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Abstract
The lack of knowledge of pharmacogenetic testing for cardiovascular disease (CVD),
coupled with their increased risk for CVD, may impair nurses’ cognitions and attitudes
toward pharmacogenetic testing for CVD. The purpose of this quantitative cross-sectional
correlational study, conducted with 230 RNs without CVD who worked in acute-care
settings in Georgia, was to determine if their years of education, years of experience, and
gender significantly influenced their perceived risk for CVD (Questions 1–3) and their
perceived knowledge of pharmacogenetic testing for CVD (Questions 4–6), and if their
perceived risk for CVD significantly influenced their acceptance of pharmacogenetic
testing for CVD (Question 7). Various regression analyses (hierarchical multiple linear
regression, multiple linear regression, hierarchical, linear regression) were conducted for
hypothesis testing. Results showed that: (a) gender significantly predicted perceived risk
for CVD, in that male nurses perceived themselves to be more at risk for CVD than did
female nurses; (b) years of education was a significant predictor of knowledge of
pharmacogenetic testing for CVD, in that as nurses’ education level increased, so did
their knowledge; and (c) knowledge of pharmacogenetic testing for CVD, but not
perceived risk for CVD, significantly predicted acceptance of pharmacogenetic testing
for CVD. This study may act as a catalyst to promote empirical work and inform practice
in nurses’ CVD health and their knowledge and acceptance of pharmacogenetic testing
for CVD.
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Chapter 1: Introduction
Cardiovascular diseases (CVDs) are disorders that affect the heart, such as
hypertension with or without renal disease, stroke, atherosclerosis, rheumatic fever,
coronary heart disease, and heart failure (American Heart Association [AHA], 2015;
Centers for Disease Control and Prevention [CDC], 2015). As of 2014, approximately 82
million adults in the United States had some form of heart disease (AHA, 2015; CDC,
2015). Moreover, one in every three individuals in the United States had at least one risk
factor for CVD (Go et al., 2013). Cardiovascular disease is the leading cause of death
among U.S. adults (AHA, 2015).
Nurses are knowledgeable about CVD (Paul & Hice, 2014), yet studies have
documented that they are at risk for CVD (Lang, Lepage, Schieber, Lamy, & KellyIrving, 2012; McElligott, Siemers, Thomas, & Kohn, 2009). Obesity, diabetes, and high
cholesterol are significantly associated with increased risk of mortality due to CVD
(AHA, 2015). In comparison to the 35.7% of American adults who are obese, 57% to
70% of nurses are obese (American Nurses Association [ANA], 2015). Across studies
examining CVD risk factors in nurses, results have shown that the average percentage of
nurses with diabetes is 10%, higher than the 8.3% of Americans in general with diabetes
(ANA, 2015). The percentage of nurses with elevated cholesterol levels has ranged from
15% to 50% across studies (Khan et al., 2012; Lang et al., 2012; Puett et al., 2009),
substantially higher than the 12.9% of American adults with high cholesterol (Cho & Lee,
2012). Sedentary behavior, poor dietary behaviors, and smoking additionally place nurses
at risk for CVD (Khan et al., 2012; Louie & Wedell, 2014). In a study conducted by the
Preventive Cardiovascular Nurses Association (2008), 43% of nurses did not engage in
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regular physical activity, 50% had very poor diets, and 18% of surveyed nurses were
smokers. Moreover, Lang et al. (2012) found that the rate CVD was elevated in nurses
due to the high rates of work-related stress and negative social interactions between
nurses and their supervisors.
The elevated risk for CVD among nurses is further complicated by their perceived
lack of risk for developing CVD (Hörnsten, Lindahl, Persson, & Edvardsson, 2014; Jones,
Weaver, Grimley, Appel, & Ard, 2006). Results from the few studies that have examined
perceived risk for CVD among nurses have shown that, despite having numerous risk
factors for CVD, nurses do not believe they are especially at risk for CVD (Hörnsten et
al., 2014; Jones et al., 2006). If nurses perceive their risk for developing CVD is low,
they may lack motivation to change behaviors that place them at increased risk for CVD
(Khan et al., 2012).
Advances in genetics, medicine, and healthcare technology have brought CVD
genomic medicine models to the patient-centered healthcare system (Humma & Terra,
2012; Johnson & Cavallari, 2013; Kee, Hayes, & McCuistion, 2014). Among the newest
of genomic medical approaches for CVD management is pharmacogenetic testing
(Howland, 2012; Johnson & Cavallari, 2013; Musunuru et al., 2012). Pharmacogenetic
testing, which is a form of genetic testing, refers to the process of identifying and
considering differences in an individual’s genetic makeup, so that practitioners can
attempt to anticipate a client’s reaction to medications and make appropriate prescriptive
decisions (Blakey & Hall, 2011; Howland, 2012; Musunuru et al., 2012; Shin, Kayer, &
Langaee, 2009).
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Acute-care nurses must have knowledge of the most current healthcare practices
and the ability to effectively transfer this knowledge to the patient-provider domain
(Chadwell, 2013; McNeils, Ironside, Zvonar, & Ebright, 2014). Acute-care nurses work
in a hospital setting with patients experiencing short-term acute medical problems; they
differ from critical-care nurses, who work in intensive-care units and emergency
medicine (Rosenthal & Guerrasio, 2009). In the future, acute-care nurses may be
expected to provide patient education related to pharmacogenetic testing (Johnson &
Cavallari, 2013).The knowledge base of nurses (and other healthcare providers) of
pharmacogenetic testing is limited as a result of the newness of such testing and the
existing controversy that surrounds it such as confidentiality of test results (Johnson &
Cavallari, 2013; Verschuren et al., 2011). Knowledge and acceptance of pharmacogenetic
testing related to CVD is also relevant in the field of nursing due to the high prevalence
rate of CVD in nurses (Lang et al., 2012; McElligott et al., 2009).
Results from this study have the potential to effect positive social change on
numerous levels and impact many stakeholders. For example, student nurses working in a
healthcare setting were increasingly focused on genomic medicine models, requiring they
have current relevant knowledge and skills to provide effective and meaningful patient
care (Maughan, Bobo, Butler, Schantz, & Schoessler, 2015). Results can inform changes
in nursing education, especially in the development of courses and curricula focusing on
genetics and pharmacogenetic testing. Health-promotion interventions for nurses have
become increasingly important with the national shortage of nurses, as participation in
such programs can reduce work-related stress and absenteeism (Kaewthummanukul &
Brown, 2006; Nahm, Warren, Zhu, An, & Brown, 2012). Due to their low perceived risk
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of CVD, despite having numerous risk factors for CVD, coupled with their lack of
knowledge and acceptance of CVD-related medical practices including pharmacogenetic
testing for CVD, acute-care nurses may not be good patient advocates and role models in
CVD risk prevention and reduction (Nahm et al., 2012). Results from the present study
can increase understanding of the demographic and work factors related to perceived risk
for CVD among nurses, which can result in targeted interventions specific to nurses’
gender, education level, and years of practice. Moreover, this study’s findings can
empower nurses to become social-change agents by adopting patient-centered practices
aimed at reducing CVD risk and increasing patient knowledge and understanding of
pharmacogenetic testing.
The purpose of this chapter is to introduce and elaborate on the proposed study
and to provide specific information on the study’s purpose and methodology. The chapter
opens with a background section that reviews the pertinent literature on study topics,
which then informs the statement of the problem. The chapter includes a summary of the
purpose of the study and the research questions and hypotheses. The chapter elucidates
the guiding theory of the study, followed by a section on the nature of the study. The
chapter then continues with sections on definitions, assumptions, scope and delimitations,
limitations, and significance. A summary concludes the chapter.
Background
Pharmacogenetic testing has been recognized in the medical community as a
means to prevent and treat CVD, and tests are currently added to a host of diagnostic
measures to identify the risks associated with CVD and to manage the disease in those
patients with CVD (Dodson, 2011; Roederer, Van Riper, Valgus, Knafl, & McLeod,
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2012; Squassina et al., 2010). Pharmacogenetic testing, which is a form of genetic testing,
refers to the process of identifying and considering differences in an individual’s genetic
makeup, so practitioners can attempt to anticipate a client’s reaction to medications and
make appropriate prescriptive decisions (Blakey & Hall, 2011; Howland, 2012).
Although pharmacogenetic testing in the clinical arena is relatively new, the use of such
testing is slowly gaining momentum (Kee et al., 2014).
Nurses in general and acute-care nurses specifically must have a strong
knowledge base regarding CVD (Johnson & Cavallari, 2013). However, researchers have
shown that acute-care nurses may have limited knowledge of CVD-related issues,
including heart-failure principles, asymptomatic hypotension, advanced risk assessment
of CVD, clinical best practices for CVD, and pharmacogenetic testing for CVD (Calzone,
Jenkins, Culp, Bonham, & Badzek, 2013; Delaney, Apostolidis, Lachapelle, & Fortinsky,
2011; Lanuza, Davidson, Dunbar, Hughes, & De Geest, 2011).
Researchers have also shown that nurses have numerous risk factors for CVD
(Lang et al., 2012; Louie & Wedell, 2014; McElligott et al., 2009; Slater, McElwee,
Fleming, & McKenna, 2005). According to a study by Louie and Wedell (2014), who
used data from the Nurses’ Health Study (NHS), 60% of acute-care nurses who
participated in the study were obese or overweight and more than 50% of participants
were severely inactive and had poor dietary habits. In another survey conducted by the
Preventive Cardiovascular Nurses Association (2008), 47% of acute-care nurses were
overweight/obese, 43% did not engage in physical activity, 50% had very poor diets, and
18% were smokers.
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Moreover, the few studies addressing CVD in nurses documented a “paradox”
between actual risk and perceived risk for CVD among nurses: they do not perceive
themselves as being at risk for CVD despite having numerous risk factors for this disease
(Hörnsten et al., 2014; Jones et al., 2006). This lack of congruence may not only impair
the health and work behaviors of nurses, but may also influence their cognitions and
attitudes toward CVD-related practices, such as pharmacogenetic testing for CVD (Chan
& Perry, 2012; Jones et al., 2006). Acute-care nurses may not be good role models for
CVD risk reduction or promotion of emerging treatments for CVD, including
pharmacogenetic testing (Louie & Wedell, 2014).
The U.S. healthcare system has become a patient-centered medical community
that is quickly moving toward a genomic model of health practice, requiring that nurses
have specific knowledge and skills with regard to CVD, genetics, and pharmacogenetic
testing to be effective healthcare providers (Kee et al., 2014). Nurses must have the most
current knowledge of CVD, increasingly need to have knowledge of pharmacogenetic
testing for CVD, must be able to advocate for such testing, and should be able to translate
the meaning of such testing to their patients (Kee et al., 2014). It remains unclear,
however, as to whether demographic factors such as gender, years of education, and years
of practice play a role in influencing nurses’ knowledge of their perceived risk for CVD
as well as pharmacogenetic testing for CVD, and if their knowledge of pharmacogenetics
for CVD influences their acceptance of its use.
Problem Statement
Nurses are known to have numerous risk factors for CVD that may not only
impair their health and work behaviors, but may also influence their work-related
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attitudes and behaviors toward CVD-related practices, such as pharmacogenetic testing
for CVD (Dodson, 2011, 2014; Knisely, Carpenter, & Von Ah, 2014; J. Zhang, While, &
Norman, 2010). The incidence of CVD can be reduced through preventive measures such
as health-promotion programs, and nurses are the ones assessing risk factors and
promoting lifestyle changes for their patients (Fair, Gulanick, & Braun, 2009). Teaching
patients and their families how to achieve CVD health (e.g., healthy eating habits,
smoking cessation, blood-pressure screening, cholesterol screening, and active lifestyle,
to mention but a few) is a core competency of the nursing profession (ANA, 2015; Kee et
al., 2014).
Genetic tests are currently added to a host of diagnostic measures to identify the
risks associated with CVD and to manage the disease in those patients with CVD (ANA,
2015; Heller, Fisher, Marks, & Hsieh, 2014). Pharmacogenetic testing, which is a form of
genetic testing, refers to the process of identifying and considering differences in an
individual’s genetic makeup, so practitioners can attempt to anticipate a client’s reaction
to medications and make appropriate prescriptive decisions (Heller et al., 2014).
Although pharmacogenetic testing in the clinical arena is relatively new, the use
of such testing is slowly gaining momentum (Heller et al., 2014). Studies conducted
during the emergence of genomic medicine in the mid- to late 2000s (Elder, 2007; Haga
& Burke, 2008; Shin et al., 2009) reported that acceptance by healthcare professionals—
especially nurses—was the most influential factor in whether patients accepted and used
a new test. Results from contemporary research (e.g., Cuffe et al., 2014; Hess, Fonseca,
Scott, & Fagerness, 2015) continue to support this argument.
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Studies conducted with groups of healthcare professionals that have included
nurses (e.g., Dodson, 2011; Dodson & Van Riper, 2011; Moen & Lamba, 2012) and were
made up solely of nurses (e.g., Kadafour, Haugh, Posin, Kayser, & Shin, 2009; Van Riper,
Barksdale, & Knafl, 2011), have documented that nurses have limited knowledge of
pharmacogenetic testing. Dodson’s (2011) review of the literature on healthcare
providers’ knowledge of pharmacogenetic testing showed that the majority (66% to 84%)
of healthcare providers, including nurses, reported minimal knowledge of
pharmacogenetic testing. In Moen and Lamba’s (2012) study, conducted with healthcare
professionals including nurses, 4% of respondents believed they were well educated
about the subject. In the same study, healthcare professionals who were 30 years or
younger and worked less than 4 years had a higher level of familiarization with
pharmacogenetics (Moen & Lamba, 2012).
Although the percentage of nurses who reported poor understanding of
pharmacogenetic testing was lower in studies conducted by Van Riper et al. (2011) and
Kadafour et al. (2009)—33% and 40% respectively—these percentages are
disconcertingly high. Although it is clear that some disparities exist in what healthcare
professionals know and how they feel about pharmacogenetic testing, currently not as
well-understood are factors that may explain some of those differences in knowledge
(Dodson, 2011; Howland, 2012). As stated by Dodson (2011), “since nursing is a key
link between physicians and patients, more research needs to be done to assess nursing
knowledge and attitudes towards pharmacogenetic testing” (p. 427).
Gaps in knowledge persist in nurses’ perceptions of their risk for CVD and their
knowledge of pharmacogenetic testing for CVD (Kee et al., 2014). As stated previously,
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studies have shown that a paradox exists between actual risks and perceived risk for CVD
among nurses in that they do not perceive themselves to be a risk for CVD (Hörnsten et
al., 2014; Jones et al., 2006). Healthcare leaders lack understanding, however, of whether
demographic factors such as gender, years of education, and years of nursing experience
may influence this perceived risk. It is important to gain clarity on these associations,
especially as these predictors tie to CVD risk (Berry et al., 2012; Go et al., 2013; Lang et
al., 2012).
It is also important to assess if gender, years of education, and years of nursing
experience play a role in the level of pharmacogenetic testing for CVD. For example, yet
another paradox exists that increased years of nursing experience aligns with lowered
degrees of knowledge of pharmacogenetic testing for CVD. Understanding the linkages
between gender, years of education, and years of nursing experience and
pharmacogenetic testing for CVD is highly pertinent to the existing literature on nurses’
ethical concerns and perceived advantages of pharmacogenetic testing (Calzone et al.,
2010; Dodson, 2011; Dodson & Van Riper, 2011). Linkages between nurses’ knowledge
and attitudes toward pharmacogenetic testing for CVD are missing in the empirical
literature. These associations also relate to ethical concerns on the part of the nurse as
well as the practitioners who develop interventions for nurses to best address these
knowledge gaps.
Purpose of the Study
The purpose of this quantitative study, using a cross-sectional design, was to
determine if acute care nurses’ gender, highest level of education, and years of nursing
experience significantly influenced their perceived risk for CVD and their knowledge of
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pharmacogenetic testing for CVD, and whether significant associations exist between
nurses’ perceived risk for CVD and their acceptance of pharmacogenetic testing for CVD.
This study had seven research questions. The first set of three questions (Questions 1–3)
determined if the independent variables of acute-care nurses’ years of education, years of
experience, and gender significantly influenced their perceived risk for CVD, the
dependent variable. The second set of three questions (Questions 4–6) assessed if the
independent variables of acute-care nurses’ years of education, years of experience, and
gender significantly influenced their perceived knowledge of pharmacogenetic testing for
CVD, the dependent variable. The seventh and last research question examined if acutecare nurses’ perceived risk for CVD, the independent variable, significantly influenced
their acceptance of pharmacogenetic testing for CVD, the dependent variable. I included
two potential covariates, health factors related to estrogen and medication-related CVD
risk, in the study as potential covariates. I conducted this study with a sample of 228
registered acute-care nurses who reside and work in acute-care hospital settings in
Atlanta, Georgia. As the study examined risk factors for CVD, the sample included only
acute-care nurses who have not been diagnosed with CVD.
Research Questions and Hypotheses
I conducted this quantitative study using a cross-sectional research design with
licensed acute-care nurses who work in Atlanta, Georgia. I posited seven questions with
associated null and alternative hypotheses for this study.
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Research Question 1
Is there a significant association between acute-care nurses’ years of education
and perceived risk for CVD, controlling for health factors related to estrogen and
medication-related CVD risk?
H01. There is no association between acute-care nurses’ years of education and
perceived risk for CVD, controlling for health factors related to estrogen and
medication-related CVD risk.
Ha1. There is a significant association between acute-care nurses’ years of
education and perceived risk for CVD, controlling for health factors related to
estrogen and medication-related CVD risk.
Research Question 2
Is there a significant association between acute-care nurses’ years of practice and
perceived risk for CVD, controlling for health factors related to estrogen and medicationrelated CVD risk?
Ho2. There is no association between acute-care nurses’ years of practice and
perceived risk for CVD, controlling for health factors related to estrogen and
medication-related CVD risk.
Ha2 There is a significant association between acute-care nurses’ years of practice
and perceived risk for CVD, controlling for health factors related to estrogen
and medication-related CVD risk.
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Research Question 3
Is there a significant association between acute-care nurses’ gender and perceived
risk for CVD, controlling for health factors related to estrogen and medication-related
CVD risk?
Ho3. There is no association between acute-care nurses’ gender and perceived
risk for CVD, controlling for health factors related to estrogen and
medication-related CVD risk.
Ha3. There is a significant association between acute-care nurses’ gender and
perceived risk for CVD, controlling for health factors related to estrogen and
medication-related CVD risk.
Research Question 4
Is there a significant association between acute-care nurses’ years of education
and knowledge of pharmacogenetic testing for CVD, controlling for health factors related
to estrogen and medication-related CVD risk?
Ho4. There is no association between acute-care nurses’ years of education and
knowledge of pharmacogenetic testing for CVD, controlling for health factors
related to estrogen and medication-related CVD risk.
Ha4. There is a significant association between acute-care nurses’ years of
education and knowledge of pharmacogenetic testing for CVD, controlling for
health factors related to estrogen and medication-related CVD risk.
Research Question 5
Is there a significant association between acute-care nurses’ years of practice and
knowledge of pharmacogenetic testing for CVD, controlling for health factors related to
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estrogen and medication-related CVD risk, controlling for health factors related to
estrogen and medication-related CVD risk?
Ho5. There is no association between acute-care nurses’ years of practice and
knowledge of pharmacogenetic testing for CVD, controlling for health factors
related to estrogen and medication-related CVD risk.
Ha5. There is a significant association between acute-care nurses’ years of
practice and knowledge of pharmacogenetic testing for CVD, controlling for
health factors related to estrogen and medication-related CVD risk.
Research Question 6
Is there a significant association between acute-care nurses’ gender and
knowledge of pharmacogenetic testing for CVD, controlling for health factors related to
estrogen and medication-related CVD risk?
Ho6. There is no association between acute-care nurses’ gender and knowledge of
pharmacogenetic testing for CVD, controlling for health factors related to
estrogen and medication-related CVD risk.
Ha6. There is a significant association between acute-care nurses’ gender and
knowledge of pharmacogenetic testing for CVD, controlling for health factors
related to estrogen and medication-related CVD risk.
Research Question 7
Is there a significant association between acute-care nurses’ perceived risk for
CVD and acceptance of pharmacogenetic testing for CVD, controlling for health factors
related to estrogen and medication-related CVD risk?
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Ho7. There is no association between acute-care nurses’ perceived risk for CVD
and acceptance of pharmacogenetic testing for CVD, controlling for health
factors related to estrogen and medication-related CVD risk.
Ha7. There is a significant association between acute-care nurses’ perceived risk
for CVD and acceptance of pharmacogenetic testing for CVD, controlling for
health factors related to estrogen and medication-related CVD risk.
Theoretical Framework
The health belief model (HBM), developed by Rosenstock and colleagues (i.e.,
Becker & Rosenstock, 1987; Hochbaum, Rosenstock, & Kegels, 1952; Rosenstock, 1974;
Rosenstock, Strecher, & Becker, 1988), was the guiding theory for this study. The HBM
posits that engaging in a preventative health behavior—the likelihood of action—depends
on the individual’s perceptions of a disease (i.e., the perceived seriousness of it coupled
with the perceived likelihood of acquiring it) and their perceptions of a new health
behavior (i.e., the benefits of engaging in a health behavior and the barriers that could
prevent the individual from adopting it; Rosenstock, 1974; Rosenstock et al., 1988).
Perceptions of the disease and the health-behavior change needed to reduce its likelihood
are influenced by modifying factors (i.e., demographic, psychological, and cognitive
factors of the individual) and cues to action (i.e., such things as doctors’ reminders and
advice from others; Rosenstock, 1974; Rosenstock et al., 1988).
As it is a health change model, it is unsurprising that the HBM has been used in
numerous nursing studies (e.g., Hong, Kim, & Suh, 2010; Shahrabani, Benzion, & Yom
Din, 2009; Tastan, Iyigün, Kilic, & Unver, 2011; J. Zhang et al., 2010). Empirical
researchers have used the HBM to explain nurses’ health behavioral changes in influenza
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vaccinations (e.g., Shahrabani et al., 2009; J. Zhang et al., 2010), cancer screenings (e.g.,
Tastan et al., 2011; Yaren, Ozklinc, Guler, & Oztop, 2008), physical activity and exercise
(Kaewthummanukul & Brown, 2006; Nahm et al., 2012), and medical services use (Hong
et al., 2010).
What is surprising is the dearth of literature that has used the HBM to explain
nurses’ health behaviors surrounding CVD and its prevention. A review of the nursing
literature published between 2000 and 2015 that involved an examination of at least two
elements of the HBM yielded one quantitative study by Jones et al. (2006). The authors
focused their study on the influence of modifying factors on perceived susceptibility of
CVD among 194 African American nurses who did not have CVD (Jones et al., 2006).
Despite having numerous risk factors for CVD (e.g., being of older age,
overweight/obese, and sedentary), nurses did not perceive themselves to be at risk for
developing CVD, even though their knowledge of CVD was quite substantial (Jones et al.,
2006).
The implications of the Jones et al. (2006) results were quite profound, especially
when considering the central role of nurses in personalized medicine that increasingly
uses genomic models (Frazier, Wung, Sparks, & Eastwood, 2009; Howland, 2012). If
nurses do not perceive themselves to be at risk for developing CVD, despite having risk
factors for CVD—and knowledge of these risk factors—they may be quick to overlook or
dismiss CVD risk factors in their patients (Jones et al., 2006). Nurses may also be less
likely to promote advances in CVD prevention and treatment, such as pharmacogenetic
testing for CVD, especially if they perceive such advances as relevant only to severe or
unusual cases of CVD (Dodson, 2011, 2014; Fair, Gulanick, & Braun, 2009; J. Zhang et
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al., 2010). A review of the literature review from 2000 uncovered no studies that were
guided by the HBM and involved CVD risk among acute-care nurses. This was a
disconcerting gap in the literature, yet it validated the need for this study.
Using the HBM, this study examined if the modifying factors of gender, highest
level of education, and years of practice significantly influenced a perception of the
disease outcome (perceived risk for CVD) and a perception of the health change
behavior outcome (knowledge of pharmacogenetic testing for CVD). The study further
examined if a perception of the disease outcome (perceived risk for CVD) significantly
influenced a likelihood of action outcome (acceptance of pharmacogenetic testing for
CVD).
Nature of the Study
I used a quantitative design for this study. The quantitative design was appropriate
as I used the scientific method; that is, I developed hypotheses that were tested through
statistical analysis of numerical data (aligned with Stangor, 2014). The study did not use
an experimental research design as the goal of the study was not to test effects from an
intervention or to determine differences between groups of acute-care nurses; rather, the
study provides an examination of relationships between naturally occurring variables (i.e.,
risk factors and knowledge and acceptance of pharmacogenetic testing; Stangor, 2014).
This study was correlational, as I sought to determine, through statistical analyses,
theory-driven relationships between the independent variables and the dependent
variables in an objective manner (as explained by Stangor, 2014). A cross-sectional
design was appropriate because I measured these variables at a one point in time rather
than over a period of time (Stangor, 2014).
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I conducted this quantitative correlational cross-sectional study with a sample of
228 registered nurses (RNs) without CVD working in acute-care settings in Georgia. This
study had seven research questions with differing independent and dependent variables.
For Questions 1–3, I conducted a hierarchical multiple linear regression (HMLR) to
assess if the independent variables of nurses’ years of education, years of experience, and
gender significantly predicted the dependent variable of perceived risk for CVD. The
variable of take medications, which could include blood pressure medications, was
included in the HMLR analysis as a covariate, as it significantly aligned with the
dependent variable. For Questions 4–6, I performed a multiple linear regression (MLR) to
determine if the independent variables of years of education, years of experience, and
gender significantly predicted the dependent variable of knowledge of pharmacogenetic
testing for CVD. For the seventh and last research question, I ran a hierarchical linear
regression (HLR) to ascertain if the independent variable of perceived risk for CVD was
a significant predictor of acceptance of pharmacogenetic testing for CVD. I included the
variable of knowledge of pharmacogenetic testing as a covariate in the HLR due to its
significant association with the dependent variable.
Definitions of Terms
Cardiovascular diseases (CVDs). Cardiovascular diseases are diseases that
involve the human body’s cardiovascular system. The main causes of CVD are blockage
of the heart and hypertension (Frazier, Johnson, & Sparks, 2009).
Deoxyribonucleic acid (DNA). DNA refers to the molecule that encodes the
genetic instructions used for the functioning of all living things and viruses (Haga &
LaPointe, 2013).
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Pharmacogenetics. Pharmacogenetics refers to the application of genomic
technologies to the discovery of new drugs to determine the variability of individual
genes in susceptibility to disease as well as drug response (Calzone et al, 2010).
Pharmacotherapy. Pharmacotherapy refers to the use of medication for disease
management (Calzone et al, 2010).
Assumptions
This study rested on certain assumptions or aspects of the research study that I
accepted as true (aligned with Stangor, 2014). The positivist paradigm that reality is
objective guides quantitative studies, assuming the researcher is knowledgeable of this
reality and the researcher can explain this objective reality by the use of the scientific
method. In accordance with the scientific method, I established a priori hypotheses and,
through the use of statistical analyses, drew objective conclusions about study findings
(as suggested by Stangor, 2014).
Methodological assumptions in this study concerned issues related to study
participants and instruments. I assumed, as study criteria, that participants were registered
acute-care nurses in Atlanta who do not have CVD. This study used an online survey
platform to obtain study data. To increase assurances that this assumption was met,
participants had to provide correct responses to screening questions before they could
take the online survey, including questions that they consented to the study, that they
were registered acute-care nurses with active nursing licenses, and that they did not have
CVD. A methodological assumption was that participants understood survey questions,
answered the survey honestly, and provided responses that truly reflected their attitudes,
beliefs, and knowledge about survey topics (as put forth by Stangor, 2014).
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Scope and Delimitations
I considered a few theoretical models prior to selecting Rosenstock’s (1974)
HBM. Bandura’s (1974) social-cognitive theory was too general and its theoretical
components (e.g., self-efficacy and modeling) did not capture the constructs examined in
this study. I also gave attention to Pender’s (1982) health-promotion model (HPM),
especially as it was developed specific to the nursing field. Key components of the HPM
(e.g., prior behaviors and social support) were not emphasized in this study model;
ultimately I decided the study topics did not adequately fit with Pender’s HPM.
Rosenstock’s (1974) HBM aligned well with the study topics and provided a meaningful
framework for the relationships between variables in this study.
The present study was limited to registered licensed acute-care nurses who work
in hospital acute-care settings in Atlanta without a CVD diagnosis. Data collection
occurred during the fall of 2015. The decision to limit the study to acute-care nurses
rested on their routine involvement with patients who have numerous types of CVDs and
the critical roles they play in CVD patient diagnosis, assessment, treatment, management,
and education. I excluded nurses who did not work in acute-care settings from this study,
and nurses who did not have access to a computer or did not have the computer skills to
be able to link to the survey and complete it. As I provided no translation of the survey,
nurses had to have the ability to read and write in English. The criteria set for inclusion
and exclusion may have reduced the generalizability of study results.
In the present study, pharmacogenetic testing was limited to CVD, as CVD
among nurses was the focal point of the study. The decision to limit the independent
variables to gender, level of education, and years of practice for the first six questions
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rested not only on Rosenstock’s (1974) HBM, but also on prior literature that identified
gender, level of education, and years of practice as risk factors for CVD in acute-care
nurses (Tucker, Harris, Pipe, & Stevens, 2010; Zapka, Lemon, Magner, & Hale, 2009)
and as factors significantly related to knowledge of pharmacogenetic testing among the
general public (e.g., Haga, O’Daniel, Tindall, Lipkus, & Agans, 2012). I included the
seventh research question examining the relationship between perceived risk for CVD
and acceptance of pharmacogenetic testing for CVD to provide a holistic examination of
pharmacogenetic testing for CVD.
Limitations
This study had a few limitations or elements of the study that were beyond the
control (as explained by Stangor, 2014). Although researcher objectivity is a desired goal
in any quantitative study, the researcher is human and is not necessarily neutral or value
free. In parallel, a possibility exists that participants differed in their understanding and
interpretation of survey questions, which may influence study data. The use of
convenience sampling in this study was a limitation. Convenience sampling increases the
likelihood that the participants are not a representative sample of the population of RNs
working in acute-care settings in Atlanta, Georgia. Another limitation of this study was
the use of a quantitative nonexperimental design, which precluded the ability to infer
cause-and-effect (aligned with Stangor, 2014).
Objectivity is of the utmost importance in empirical research, and a certain degree
of objectivity is not only necessary but required to reach sound study conclusions
(Stangor, 2014). However, research conducted with human subjects, especially research
using nonexperimental methods, has some methodological and design limitations that can
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reduce study objectivity and quality. Study objectivity can improve as researchers
establish sound study-validity processes (Jackson, 2015).
Study Internal Validity
Internal validity “speaks to the validity of the research itself” (Stangor, 2014,
p. 34). It pertains to the degree of accuracy of the relationship between the independent
and dependent variables (Stangor, 2014). Nonexperimental research studies are limited
by certain issues that reduce the internal validity of a study, otherwise known as threats
to internal validity (Jackson, 2015). One threat to internal validity, confound bias, has the
potential to make the study as a whole invalid (Jackson, 2015). Confound bias results in
the inability to conclude that the dependent variable effects were a result of the
independent variable or were due to an unmeasured “third variable”—a variable that
significantly aligns with the independent and the dependent variables (Armistead, 2014,
p. 2).
Although researchers cannot completely eliminate the “third variable problem”
(Armistead, 2014, p. 2), it was reduced in this study by controlling for covariates:
variables known to relate to the independent and the dependent variable (Jackson, 2015).
This study had two potential covariates. The first covariate was estrogen-related health
factors/events (e.g., postmenopausal status, hormone-replacement therapy, or birth
control pills). The second covariate was medication(s) used for health conditions other
than CVD but that nonetheless increase CVD risk (e.g., birth control or prednisone) or
decrease CVD risk (e.g., diuretics). I determined significant associations between the two
covariates and the three dependent variables by significant (i.e., p < .05) Spearman’s rho
correlation coefficients (Stangor, 2014), if found to be significantly associated with any
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of the three dependent variables in this study, I controlled for covariates in the statistical
analyses for hypothesis testing, HMLR, by entering them in the first step or model of the
HMLR (Jackson, 2015).
One other bias common to nonexperimental research studies, especially those
using self-report instruments, is social desirability bias, where participants provide
answers to survey questions that are not truthful but present a “favorable image” of the
participant (Armistead, 2014, p. 5). Social desirability bias increases when researchers
ask participants sensitive questions (Armistead, 2014). Although this study did not
include questions that were highly sensitive, participants may have provided answers on
the perceived risk for CVD scale that were socially desirable in that nurses may have
thought they should have few or no risk factors for CVD. I reviewed participant data for
extreme scores and outliers and adjusted accordingly (i.e., winsorized outliers; Armistead,
2014).
Significance of the Study
Acute-care nurses have numerous modifiable risk factors for CVD (Lang et al.,
2012; Louie & Wedell, 2014; McElligott et al., 2009; Slater et al., 2005). Lang et al.
(2012) found that acute-care nurses had elevated CVD due to the high rates of workrelated stress and negative social interactions between acute-care nurses and their
supervisors. According to a study by Louie and Wedell (2014), who used data from the
NHS, 60% of acute-care nurses who participated were obese or overweight and more
than 50% of participants were severely inactive and had poor dietary habits.
In the present study, I collected data from nurse participants in Georgia. The State
of Georgia is one of the least healthy states in the United States (Hensley, 2014). Of
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Georgians, 30% are obese and 76% have unhealthy diets (Hensley, 2014). In 2010,
28.2% of deaths and 120,000 hospitalizations cost $5.5 billion, attributed to CVD and
stroke in Georgia (Hensley, 2014). The total direct and indirect cost resulting from CVD
in Georgia is about $7.5 billion annually (Hensley, 2014). Because CVD is more
prevalent in the State of Georgia than elsewhere, acute-care nurses who work and reside
in Georgia are likely to have CVD risk factors (Hensley, 2014). To date, no study has
examined CVD risk factors of acute-care nurses in the Atlanta area. Further, no study has
examined the association between CVD risk factors and pharmacogenetic testing in
acute-care nurses.
Social change can result from this study’s findings including a direct impact on
nursing knowledge and training through the development of targeted educational
materials for acute-care nurses (and ultimately, patients) about CVD risk factors and
pharmacogenetic testing on patient health outcomes and on the empowerment of acutecare nurses to act as patient advocates. Developing a better understanding of
demographic and CVD risk factors among acute-care nurses will allow for specific
intervention and targeted educational programs in nursing schools and training programs
in healthcare organizations. Moreover, results from this study may facilitate future
research on how acute-care nurses’ perceptions of CVD risk factors and pharmacogenetic
testing influence their patient-care practices and patient advocacy, including increasing
patient awareness and knowledge of CVD risk factors and the benefits of
pharmacogenetic testing,
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Summary
CVD and pharmacogenetics related to CVD are relevant in the field of nursing
due to the high prevalence of CVD in acute-care nurses (McElligott et al., 2009). Acutecare nurses are knowledgeable about CVD, yet studies have documented that they are at
risk (Lang et al., 2012; McElligott et al., 2009). Research has also shown that acute-care
nurses have numerous risk factors for CVD (McElligott et al., 2009; Slater et al., 2005).
Due to their increased risk for CVD, their lack of knowledge of pharmacogenetic testing,
and their concerns about such testing, acute-care nurses may not be good role models in
CVD risk reduction, which may impact their patient-education behaviors (Louie &
Wedell, 2014).
Hence, the need exists for this study as well as a better understanding of the
literature presented in Chapter 2. Chapter 2 provides a comprehensive review of the
theoretical framework guiding the study. Also, the chapter presents pertinent literature on
acute-care nurses’ perceived risk for CVD, and their knowledge and attitudes toward
pharmacogenetic testing.
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Chapter 2: Literature Review
Acute-care nurses carry an increased burden of CVD, and their perceptions of
their own risk for CVD may play a role in their patient-centered communication,
behaviors, and practices (Dodson, 2011, 2014). This increased focus on personalized
healthcare has dovetailed with new and emerging genetic medicine models and practices,
including pharmacogenetic testing for CVD. These practices are so new that researchers
have yet to assess the various recommended pharmacogenetic methods, practices, and
tests available to physicians, pharmacists, and acute-care nurses (Johnson & Cavallari,
2013). Using Rosenstock’s (1974) HBM, I addressed the gaps in the literature by
examining relationships between the independent variables of gender, highest level of
education, and years of practice, and the dependent variables of perceived risk for CVD
and knowledge of pharmacogenetic testing. I also examined the association between
perceived risk for CVD and acceptance of pharmacogenetic testing in acute-care nurses.
My objective in this chapter is to provide a review of the relevant literature as it
pertains to the study topics. The chapter opens with a summary of the literature search
strategy. A comprehensive review of the HBM follows, including discussions of HBM
theoretical constructs and a summary of the HBM literature on acute-care nurses, CVD,
and genetic testing. I then review CVD and risk factors for CVD, followed by a review of
the literature on acute-care nurses’ risk factors for CVD. The chapter changes to a
discussion and review of the pertinent literature on acute-care nurses’ knowledge and
attitudes toward pharmacogenetic testing. As this literature is so new, studies reviewed
addressed pharmacogenetic testing for any disease; not just CVD. A conclusion ends the
chapter.
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Literature Search Strategy
The literature search for this study started with Walden University library and the
use of ProQuest, which is linked to CINAHL, a cumulative index of Nursing and Allied
Health Periodicals, Medline, PubMed, EBSCOhost, and Google Scholar. The search
centered on peer-reviewed journal articles in the fields of nursing, medicine, psychology,
and public health. The key terms used to search for relevant peer-reviewed journal
articles included nurses health, acute care nurses’ health, nurses’ perceived risk for
cardiovascular disease, acute care nurses and health risks, cardiovascular disease in
healthcare providers, acute care nurses and cardiovascular disease, risk factors for
cardiovascular disease in nurses, pharmacogenetic testing, pharmacogenomic testing,
healthcare and pharmacogenetic testing, nurses and pharmacogenetic testing,
acceptance of pharmacogenetic testing, knowledge of pharmacogenetic testing,
measurement of pharmacogenetic testing knowledge and attitudes, “attitudes toward
pharmacogenetic testing, health belief model and nurses, and health belief model and
pharmacogenetic testing. White papers, reports, data tables, and publications from
national health organizations such as the World Heart Federation (WHF, 2014), AHA
(2015), and CDC (2015) augmented empirical works.
Theoretical Framework: Rosenstock’s (1974) Health Belief Model
The theory that guided this research study was the HBM developed by
Rosenstock and colleagues (i.e., Becker & Rosenstock, 1987; Cummings, Jette, &
Rosenstock, 1978; Rosenstock, 1974; Rosenstock, Strecher, & Becker, 1994). The
underlying premise of the HBM is that perceptions of a disease and perceptions of a new
health behavior are influenced by modifying factors to, in turn, influence likelihood of
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action of engaging in a new health behavior (e.g., increased exercise) or change a
negative health behavior (e.g., smoking cessation; Rosenstock, 1974; Rosenstock et al.,
1988, 1994). I discuss the components and constructs of the HBM in the following
sections.
Disease Perceptions: Perceived Susceptibility, Seriousness, and Threat
Three components of the HBM pertain to the construct of perceptions of the
disease. Two of these factors are the perceived susceptibility to or risk of acquiring a
health issue and perceived severity or seriousness of a health issue (Rosenstock, 1974;
Rosenstock et al., 1988, 1994). Perceived susceptibility pertains to an individual’s
assessment of risk or likelihood of acquiring a health issue, disorder, or disease.
Rosenstock (1974) argued that individuals who believe they are at greater risk than others
in acquiring a disease are more likely to engage in behaviors that decrease this risk.
Perceived seriousness refers to the individual’s thoughts and cognitions on the severity of
a disease (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Rosenstock (1974) posited
that perceptions of the seriousness of health issues is most often informed by an
individual’s knowledge and understanding of it.
The third perception of the disease component is perceived threat of the health
issue, which is considered a modifying factor (Rosenstock, 1974; Rosenstock et al., 1988,
1994). The construct of perceived threat of a health issue has been neglected in
theoretical conversations due to empirical inconsistency in its operational definition;
indeed, some texts do not contain its definition nor do they describe this perception of the
disease factor in any detail (Rosenstock et al., 1987, 1994). Perceived threat of the
disease has been considered a response efficacy and has been used as a proxy for self-
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efficacy (Rogers, 1983); alternatively, it has been operationally defined as an extension of
perceived susceptibility (Mikhail, 1981). The most consistent definition in the HBM
literature of perceived threats is “a sequential function of perceived severity and
perceived susceptibility” (Champion & Skinner, 2008, p. 47), which was the definition
used in this study, considered a perception of the disease indicator.
Health Behavior Perceptions: Perceived Benefits versus Barriers
Two components concern perceptions of the new health behavior: the perceived
benefits of a new health behavior and the perceived barriers or obstacles to adopting the
new health behavior (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Rosenstock
(1974) posited that, when considering a new health behavior, individuals balance the
perceived benefits with the perceived barriers, and these two components act together to
increase the likelihood of action of adopting a new health behavior. The component of
perceived benefits refers to individuals’ opinions of the value, importance, and usefulness
of engaging in a certain health behavior to decrease the risk or likelihood of acquiring a
disease or disorder. Simply stated, individuals are likely to adopt and continue engaging
in a health behavior if they hold a firm belief in its efficacy in preventing a disease
(Rosenstock, 1974).
Perceived barriers pertain to individual obstacles that prevent an individual from
adopting the new health behavior. Although some barriers are contextual (e.g., lack of
financial or personal resources to obtain medical services), many are intrapersonal and
can include fear, inconvenience, and distress of engaging in a new behavior (Rosenstock,
1974; Rosenstock et al., 1988, 1994). Ultimately, an individual is more likely to take a
health action if they perceive the benefits of the new health behavior outweigh the
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barriers (Rosenstock, 1974; Rosenstock et al., 1988, 1994). As perceived benefits and
perceived barriers pertain to the health behavior itself, knowledge of a health behavior
can indicate this balance (Champion & Skinner, 2008).
Modifying Factors
The components that comprise the construct of modifying factors are individual
factors. These include: (a) personal demographics, such as ethnicity, age, or gender,
which were modifying factors examined in this study; (b) personality and psychological
factors; and (c) prior experience with and knowledge of the disease, but not knowledge of
the new health behavior (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Modifying
factors influence perceptions of the disease and perceptions of the health-behavior factors
(Rosenstock, 1974; Rosenstock et al., 1988, 1994).
Cues to Action
Cues-to-action constructs are stimuli that elicit the decision-making process to
adopt a new health behavior. Cues to action factors can be internal or external to the
individual. Internal cues to action include disease symptomatology (e.g., fever or pain)
whereas external cues to actions can be events, situations, or individuals who influence
the individual to adopt a new health behavior (Rosenstock, 1974; Rosenstock et al., 1988,
1994). Acute-care nurses themselves can act as cues to action in patient health behavioral
change (McNeils et al., 2014).
Relationships Between Health Belief Model Factors
Rosenstock (1974) posited that modifying factors directly influence the
perceptions of the disease variables of perceived susceptibility, perceived seriousness
(severity), and perceived threat. Modifying factors also directly influence the perceptions
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of perceived benefits and perceived barriers to new health behavior and inform the
decision-making process when balancing perceived benefits with perceived barriers
(Rosenstock, 1974). Perceptions of the disease and perceptions of the new health
behavior in turn influence the likelihood of action: the adoption of a new health behavior
or a change in health behavior (Rosenstock, 1974). I comprehensively discuss the
theoretical relationships that this study addressed after a presentation of the literature on
the HBM and acute-care nurses’ health behaviors.
The Health Belief Model in Nursing Research
The HBM is one of the most common theoretical frameworks used in health
research (Bakas et al., 2012) and a substantial body of literature has been published on
HBM-guided nursing interventions that promote health and prevent disease in patients
(Boyde, Turner, Thompson, & Stewart, 2011; Heller et al., 2014; McNeils et al., 2014).
The body of literature using the HBM to frame nurses’ own health behaviors is quite
insubstantial, especially when considered in the context of CVD. Of the few studies that
have used the HBM to advance understanding of nurses’ health behaviors, the majority
have focused on nurses’ attitudes and behaviors about being vaccinated for influenza
(Coe, Gatewood, Moczygemba, Goode, & Beckner, 2012; Ofstead, Tucker, Beebe, &
Poland, 2008; Prematunge et al., 2012; Shahrabani et al., 2009; J. Zhang et al., 2010).
Studies by Coe et al. (2012), Ofstead et al. (2008), and Prematunge et al. (2012) found
significant associations between the HBM factors of perceived susceptibility and
perceived seriousness of influenza and increased likelihood of getting vaccinated against
influenza among nurses. Shahrabani et al. (2009), in a study with 299 Israeli nurses,
found that perceived susceptibility and perceived seriousness of influenza significantly
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predicted the likelihood of acute-care nurses getting an influenza vaccination. Results
further showed that nurses’ increased knowledge of influenza, considered a modifying
factor in the study, significantly predicted they would get vaccinated (Shahrabani et al.,
2009).
J. Zhang et al. (2010) conducted a review of the literature of 12 studies that
examined the relationships between HBM factors and nurses’ vaccination statuses. The
overarching conclusions from the J. Zhang et al. (2010) review of studies, which were all
correlational and used self-report data, was that as nurses’ knowledge of influenza and
perceived seriousness of influenza increased, so did their likelihood of getting the
influenza vaccination. Results further showed that acute-care nurses’ receipt of the
influenza vaccine directly aligned with the increased likelihood that they would
encourage their patients to receive the influenza vaccination (J. Zhang et al., 2010). This
finding is relevant to this study, as it demonstrated that acute-care nurses’ own health
behaviors align with advocacy for health behaviors in their patients.
Other studies that used the HBM with nurse participants tended to focus on health
promotion and preventative behaviors, such as cancer screenings (e.g., Yaren et al.,
2008); breast self-examinations (e.g., Tastan et al., 2011); hand washing (Ghanbari,
Farazi, Shamsi, Khorsandi, & Esharti, 2014); and the prevention of workplace injuries
(Tveito et al., 2014). Other studies conducted with nurses (Chan & Perry, 2012; Chi et al.,
2015) were evaluations of HBM-guided health-promotion interventions for nurses and
their effects on nurses’ health behaviors. In a unique and rigorously designed
randomized-controlled-trial (RCT) study with 100 Taiwanese pregnant nurses, Chi et al.
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(2015) determined that participation in a second-hand smoking intervention resulted in
nurses’ increased knowledge of and decreased exposure to second-hand smoke.
The scarcity of HBM-guided intervention evaluation studies conducted with
acute-care nurses as participants was evidenced in Chan and Perry’s (2012) review of the
literature. Chan and Perry reviewed only three studies, found after Chan and Perry
widened their literature search beyond RCTs to include any studies “that tested an
appropriate intervention” with acute-care nurses (2012, p. 12). Of these three studies,
none were methodologically rigorous. Researchers conducted the studies with three
different nursing samples (in the United States, in Canada, and in Taiwan), which
lessened the generalizability of findings. Furthermore, the three studies aimed to promote
or decrease a variety of health behaviors (e.g., increased exercise, reduced smoking of
cigarettes, or reduced use of alcohol).
Despite these methodological concerns, Chan and Perry (2012) demonstrated that
all three studies showed that nurses’ participation in health-promotion interventions
resulted in significant changes in nurses’ health behaviors, including reduction in the
number of cigarettes smoked per day and increased workplace exercise-based activity
levels. The Chan and Perry study draws attention to the HBM theoretical relevance of
studying nurses’ health behaviors as well as the dearth of HBM-driven studies on nurses.
Health-belief model, nurses, and cardiovascular disease. Researchers
conducted an overwhelming majority of studies using the HBM as a foundation to
explore CVD-related interventions, practices, and behaviors with patients (e.g., Abed,
Khalil, & Moser, 2015; Baghianimoghadam et al., 2013; Boyde et al., 2011). A general
finding emerging from these studies was that increased knowledge of CVD risk factors
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among patients did not significantly influence patients’ perceived susceptibility for CVD
(Abed et al., 2015; Baghianimoghadam et al., 2013; Boyde et al., 2011). This body of
literature showed that individuals who display numerous clinical indicators for CVD
frequently perceived themselves to be at small to moderate risk for CVD (Abed et al.,
2015; Boyde et al., 2011).
A gap in knowledge, however, exists with regard to nurses. A review of the
literature yielded two HBM-guided studies (e.g., Hörnsten et al., 2014; Jones et al., 2006),
one quantitative and one qualitative, conducted with acute-care and primary-care nurses
and pertained to nurses’ own CVD-disease prevention behaviors. The Jones et al. (2006)
study examined associations between modifying factors and perceived susceptibility and
seriousness of CVD among 194 African American acute-care nurses who did not have
CVD. Despite having risk factors for CVD (e.g., being of older age, overweight/obese,
and sedentary) and considerable knowledge of CVD, acute-care nurses did not perceive
themselves to be at risk for developing CVD. Although acute-care nurses who were older
had more knowledge of CVD than did younger acute-care nurses, age did not moderate
knowledge of CVD and increased perceived risk for CVD. The incongruence between
perceptions of risk for and seriousness of CVD seen in the Jones et al. study suggested a
need for theoretically driven studies on CVD risk factors among more diverse groups of
acute-care nurses. The Jones et al. study focused only on female acute-care nurses; the
researchers did not consider gender to be a modifying factor, nor were highest level of
education or years of practice considered, which were examined as modifying factors in
this study.
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In contrast to Jones et al. (2006), Hörnsten et al. (2014) conducted a qualitative
case study guided by the HBM and conducted with 10 primary care nurses in Sweden.
The objective of the Hörnsten et al. study was not to examine primary-care nurses’ health
behaviors as they related to CVD but rather healthcare provider–patient communication
strategies that primary-care nurses used to promote health behaviors among patients who
were at risk for CVD. Analysis of interviews yielded five themes centered on acute-care
nurses’ communication practices with patients on CVD. The first theme concerned nurses’
acknowledgement of the importance of listening to patients’ concerns rather than
directing and controlling the conversation. The second themes were the importance of
instilling confidence and not fear in patients about their susceptibility to CVD. Two
themes that shared commonalities were (a) guiding patients toward better lifestyle
choices rather than pressuring them to change poor health behaviors and (b) engaging in
motivational communication practices that encourage lifestyle changes among patients
rather than demanding patients take responsibility for their behaviors. The last theme was
that primary-care nurses played a key role in promoting patients’ communication
regarding psychologically distressing health topics with their healthcare provider rather
than patients avoiding such topics (Hörnsten et al., 2014).
Health-belief model, nurses, and genetic testing. Although somewhat dated, the
review of the literature on healthcare provider–patient communication practices regarding
genetic testing by Edwards (2009) is a meaningful and relevant empirical work that had
implications for the present study. The goal of the Edwards study was to systematically
review literature on healthcare provider–patient communication on genetic testing and its
influence on patient outcomes. Edwards focused on studies that avoided the topic of
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genetic counseling and instead specifically addressed healthcare provider–patient “risk
communication” interventions for genetic testing, or “the open two-way exchange of
information and opinion about risk, leading to better [patient] understanding and better
[healthcare provider-driven] decisions” (p. 4).
The Edwards (2009) review of literature included studies that ranged from
rigorously designed RCTs to qualitative case studies of genetic-testing information
exchanges or interventions, resulting in a total of 28 studies. The majority (> 80%) of
studies involved genetic counselors or psychologists as healthcare providers. To increase
the number of studies reviewed, Edwards included studies that focused on the efficacy of
any type of “genetic testing intervention,” inclusive of RCTs, face-to-face informational
meetings between a healthcare professional and a patient, risk assessments, “pedigree
construction,” videos, and interactive digital products (2009, p. 17). The type of specific
genetic-testing interventions included general psychosocial counseling, psychosocial
counseling specific to a patient-outcome domain (e.g., stress management, problem
solving, or decision making), “cognitive-affective preparation” concerning a negative
genetic-testing outcome, and basic informational sessions (Edwards, 2009, p. 18).
Edwards (2009) compared studies and noted those where the interventions were
effective and feasible. The researchers also examined the influence of the intervention on
patient outcomes. Patient outcomes varied, as the interventions differed in intent. For
example, some studies examined interventions that focused on patients’ interest in
receiving genetic testing (e.g., for a specific disease, such as breast cancer) whereas other
studies addressed interventions to assist patients with a newly diagnosed genetic
condition found through genetic testing. The most common dependent variables
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examined were (a) patient knowledge and understanding of the outcomes of a genetic test,
conducted for themselves or for a family member (e.g., a child with Down syndrome);
(b) patient perceived risk of developing a genetic-based disorder or disease risk (e.g.,
breast cancer due to having the BRCA1/2 gene mutation); and (c) patient-perceived
health-behavior change (e.g., undergoing BRCA1/2 testing, mammography, or breast
examination; Edwards, 2009).
Despite the varied types of studies reviewed, Edwards (2009) did find consistency
in results with regard to significant and positive associations between riskcommunication interventions and increases in patients’ disease and genetic-testing
knowledge and perceived risk for acquiring a disease. However, risk-communication
interventions did not systematically influence patient affective states, health status, or
health behavior change. Edwards also found that patient characteristics of “low-tomoderate risk” status and higher levels of education aligned with increased
responsiveness to participation in risk-communication interventions (p. 18).
One assumption of the HBM is that individuals have the capacity to change their
health-related behaviors for health promotion and disease prevention (Rosenstock, 1974;
Rosenstock et al., 1988, 1994). The body of literature on the HBM supports an additional
argument that not only do acute-care nurses have the ability to influence others’ health
behavior by increasing their knowledge of a disease or genetic testing, but they
themselves would be more accepting of the adoption of new health behaviors (Johnson &
Cavallari, 2013). In other words, if acute-care nurses are knowledgeable enough about
pharmacogenetic testing through acceptance and awareness, they would be able to teach
their patients about this new technology.
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Application of the Health Belief Model to the Proposed Study
The present study focused on (a) the modifying factors of gender, highest level of
education, and years of practice; (b) perceived susceptibility or risk for CVD;
(c) perceived benefits versus barriers to health behavior, measured as knowledge of
pharmacogenetic testing for CVD; and (d) likelihood of action, measured by acceptance
of pharmacogenetic testing for CVD. Figure 2 presents the pathways examined in this
study. The pathway from modifying factors to perceived susceptibility, Path A, was
addressed by Research Questions 1 through 3. These three research questions inquired if
acute-care nurses’ gender, years of education, and years of practice (the independent
variables) significantly influence perceived susceptibility for CVD (the dependent
variable). The pathway from modifying factors to perceptions of benefits over barriers,
Path B, was addressed in Research Questions 4 through 6. These three questions inquired
if acute-care nurses’ gender, years of education, and years of practice (the independent
variables) significantly influenced their knowledge of pharmacogenetic testing for CVD
(the dependent variable). The final pathway between the perceived susceptibility to
likelihood of action, Path C, inquired as to whether perceived susceptibility for CVD
significantly influenced the likelihood of the action behavior of accepting
pharmacogenetic testing for CVD.
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Modifying Factors
Gender, Highest Level of
Education, and Years of Practice
Path A

Path B

Perception of
Susceptibility

Perception of Benefits versus
Barriers

Perceived Susceptibility
for CVD

Knowledge of
Pharmacogenetic Testing for
CVD

Path C
Likelihood of Action
Acceptance of Pharmacogenetic
Testing for CVD
Figure 1. Proposed study pathways using the HBM (Note. This figure was created
specifically for the study)
Cardiovascular Disease
CVDs are diseases that affect the heart and blood vessels such as ischemic heart
disease, cerebrovascular disease (stroke), heart failure, and coronary artery disease (CDC,
2015). Mortality and morbidity associated with CVD in the United States has diminished
drastically as a result of improvement in disease prevention, diagnoses, and treatment
options. Although CVD incidence has diminished, it still impacts the health and wellbeing of many Americans. Three major risk factors associated with CVD are
uncontrolled hypertension, elevated cholesterol levels, and smoking. In 2007–2008,
49.7% of individuals aged 20 years or older had at least one of the risk factors associated
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with CVD, 21.3% had the two of three risk factors, and 2.4% had all three risk factors
associated with CVD. Nationally, CVD causes one in three deaths each year (CDC, 2015).
Cardiovascular Risk Factors
Despite the high incidence of CVD, CVD has declined from 6.7% in 2000 to
6.0% in 2010 (CDC, 2015). The drop in CVD is partly due to recognition of the risk
factors for CVD (CDC, 2015; Go et al., 2013; WHF, 2014). However, some risk factors
cannot be changed; that is, they are inherent to the individual and are unmodifiable. Other
risk factors for CVD can be changed, and are considered modifiable (CDC, 2015; Go et
al., 2013; Roger et al., 2012: WHF, 2014).
Unmodifiable cardiovascular disease risk factors. The most common
unmodifiable risk factors are age, gender, family history, and ethnicity (CDC, 2015;
Roger et al., 2012). Studies (Berry et al., 2012; Go et al., 2013; Lang et al., 2012) and
public health reports (CDC, 2015; WHF, 2014) have consistently documented significant
associations between aging and increased risk of developing CVD. Subtle physiological
changes can occur in the cardiovascular system even in the absence of CVD (AHA, 2015;
Roger et al., 2012; WHF, 2014). Aging aligns with advanced growth of plaque
formations that result from genetic or lifestyle factors (Go et al., 2013; Qi, Meigs,
Rexrode, Hu, & Qi, 2013). Moreover, among older individuals, the heart muscles relax
less completely between beats, stiffening the heart chamber and lessening its
effectiveness in pumping blood throughout the body (AHA, 2015; Go et al., 2013; Roger
et al., 2012).
It is difficult to discuss unmodifiable risk factors in isolation from one another:
aging, gender, ethnicity, and family history all interact to influence risk for CVD (CDC,
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2015; Cho & Lee, 2012). A report on CVD by age, gender, and ethnic groups by the
AHA (2015) documented that 6.3% of U.S. men and 5.6% of U.S. women aged 40 to 59
years of age have CVD. These percentages increase to 19.9% and 9.7% for men and
women aged 60 to 79 years of age, respectively (AHA, 2015). However, male gender
aligns with increased likelihood of CVD only when comparing men to nonmenopausal
women (Cho & Lee, 2012; WHF, 2014). When women reach menopausal age, the risk of
CVD equals that of men (Cho & Lee, 2012; WHF, 2014). The increased likelihood of
CVD for women after menopause has been credited to loss of estrogen (Cho & Lee,
2012; Crandall & Barrett-Connor, 2013). Moreover, postmenopausal women have
significantly higher levels of obesity and hypercholesterolemia than do men of the same
age; obesity and hypercholesterolemia are modifiable risk factors for CVD (ANA, 2015;
Baum et al., 2012; Go et al., 2013). Nonetheless, studies have shown that African
American men have the greatest risk for CVD in comparison to African American
women and Caucasian men and women, and remain at greatest risk across age groups
(AHA, 2015; Go et al., 2013).
Modifiable cardiovascular disease risk factors. Modifiable risk factors are
those factors that can be controlled and treated such as high blood pressure, elevated
cholesterol, overweight, tobacco use, sedentary lifestyle, poor diet, and diabetes; in other
words, those risks that can be changed or modified through behavioral change (AHA,
2015; Roger et al., 2012; WHF, 2014). Medical treatment has little impact in preventing
premature death. However, individuals can prevent premature death by preventing
unhealthy habits, which accounts for 40% of all premature deaths (AHA, 2015; Roger et
al., 2012; WHF, 2014).
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Hypertension. Hypertension is the leading cause of CVD globally, determined by
constant elevation of systolic pressure (the top number) at 140 millimeters of mercury or
higher (when the heart is at work) or when diastolic (the bottom number) pressure is 90
millimeters of mercury or above (when the heart is at rest; CDC, 2015; Louie & Wedell,
2014; Roger et al., 2012). Prehypertension is when systolic blood pressure is 120–139
mm Hg or diastolic blood pressure of 80–89 mm Hg (CDC, 2015; Louie & Wedell, 2014).
According to the CDC (2015), hypertension is a leading CVD-risk factor. Lack of
physical activity, poor diet, and heavy smoking can lead to uncontrollable hypertension,
hence CVD risk (Go et al., 2013; Roger et al., 2012).
Smoking. According to the World Health Organization (WHO, 2015),
approximately 1 billion people in the world smoke and as such, the risk of being
diagnosed with CVD is extremely high among female smokers, younger male smokers,
and heavy smokers, and smoking causes about 10% of all CVD deaths. In the United
States, 350,000 men and 80,000 women die prematurely each year from CVD as a result
of smoking (Louie & Wedell, 2014; WHO, 2015). By 2020, smokers will increase their
rate of smoking to 6.7 trillion cigarettes globally, and by 2030 tobacco-related deaths will
increase to 80% of all deaths (Lang et al., 2012; WHO, 2015).
Elevated cholesterol/Poor diet. Elevation of blood-level cholesterol remains one
CVD risk factor and causes 2.6 million deaths (4.5% of all CVD deaths globally; Mendis,
Puska, & Norrving, 2011). The incidence of CVD has increased significantly due to
changes in dietary habits. In a study conducted by Burke, Thompson, Roos, Verdouw,
and Troe (2011) about CVD prevention, the consumption of foods high in fats, processed
foods, and simple sugars has increased the development of CVD. In the same study,
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researchers found an increase of 250 kcal intakes per capita per day and also an increase
in fat intake per capita per day of 14 grams (Burke et al., 2011). This suggests that diet
rich in fruits and vegetables, water, and less salt intake will improve cardiovascular
health (Roger et al., 2012).
Diabetes. Diabetes mellitus is one of the modifiable risk factors associated with
CVD affecting more than 16 million individuals in the United States alone (Louie &
Wedell, 2014),for those with the two types of diabetes—type 1 and type 2—individuals
have twice the chance of being diagnosed with CVD. CVD mortality occurs more in
individuals diagnosed with diabetes. The risk factor for type 2 diabetes is being obese,
coupled with lack of exercise and poor diet. In the NHS, 60% of participants (acute-care
nurses) were obese or overweight; more than 50% were severely inactive and had poor
dietary habits (Louie & Wedell, 2014).
Overweight/Obesity. Obesity, indicated by a body mass index equal or greater
than 30, is one of the strongest predictors of CVD (Louie & Wedell, 2014). Excessive
body weight significantly impacts other CVD risk factors such as hypertension, lowdensity lipoprotein, triglycerides, and diabetes. These lead to increased risk of CVD,
hence premature death (Louie & Wedell, 2014). In several epidemiological studies,
overweight individuals have a 32% chance of being diagnosed with CVD and obese
individuals have an 81% chance (Alexander, 2001). In a meta-analysis of 26
observational studies, (390,000 men and women) conducted at the Harvard School of
Public Health, “women with a body-mass index of 30 or higher had 62% greater risk of
dying from [coronary artery disease] and CVD” (Alexander, 2001, p. 45).
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Cardiovascular Disease Risk Factors and Genetics: Nurses’ Health Study Research
As stated previously, family history is an unmodifiable risk for CVD (AHA,
2015; Louie & Wedell, 2014), and 43% of American adults have a family history of CVD
(Zlot, Valdez, Han, Silvey, & Leman, 2010). Family history as a risk factor for CVD has
led to studies examining the roles genes play in the development of CVD, with much of
this research recognizing the complex interaction among genotypes, the individual, and
the environment (J. Zhang et al., 2010). Studies that have used Harvard’s NHS data (e.g.,
Baum et al., 2012; Crandall & Barrett-Connor, 2013; de Oliveira Otto et al., 2013; Fretts
et al., 2014; Qi et al., 2013) are at the forefront of this literature. Most researchers using
NHS data tend to identity participants as women and not acute-care nurses; therefore, it is
important to acknowledge that results from studies pertain to women and to acute-care
nurses.
The contribution of NHS research studies to the understanding of genetic and
physiological contributions to CVD cannot be overstated. Studies using NHS data are
expansive and comprehensive, with numerous studies examining various genetic
antecedents of CVD. This has led to some consistencies in the findings. Contemporary
studies using NHS data shown significant and consistent associations between shortened
telomere length and increased risk for CVD (Crous-Bou et al., 2014; Devore, Prescott,
De Vivo, & Grodstein, 2011; Du et al., 2013; Gu et al., 2015). Studies using NHS data
led to increased knowledge of the genetic variants involved in phospholipid synthesis
(Ferrell & Chiang, 2015, Fretts et al., 2014), inflammatory and fatty-acid processes
(Baum et al., 2012; de Oliveira Otto et al., 2013; Hak, Karlson, Feskanich, Stampfer, &
Costenbader, 2009), and glucose and estrogen regulation (Burns & Korach, 2012;
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Crandall & Barrett-Connor, 2013; Qi et al., 2013; Qi, Workalemahu, Zhang, Hu, & Qi,
2012; H. Zhang, Mo, Hao, & Gu, 2012), all of which increase the odds of having CVD.
With consistent acknowledgement of the genes-environment complexities
involved in the development of CVD, the body of literature using NHS has contributed to
the practice of patient-centered practices by identifying individuals at risk for CVD, as
well as behaviors that reduce CVD risk (Squassina et al., 2010). Results from NHS
studies showed that the risk for CVD is more likely among women (and nurses) with
(a) metabolic syndrome and Type 2 diabetes (Du et al., 2013; Ferrell & Chiang, 2015;
Kalea, Harrison, Stephens, & Talmud, 2012; Qi et al., 2013, 2012; Stanhope, Schwartz,
& Havel, 2013); (b) estrogen-related disorders, including early menopause (Burns &
Korach, 2012; Crandall & Barrett-Connor, 2013; Shuster, Rhodes, Gostout, Grossardt, &
Rocca, 2010); (c) depression (Hek et al., 2013); (d) sleep disorders, including sleep apnea
and restless leg syndrome (Ferrell & Chiang, 2015; Innes, Selfe, & Agarwal, 2012;
Sharma et al., 2011); (e) Vitamin B and D deficiencies (Bartali, Devore, Grodstein, &
Kang, 2014; Gunta, Thadhani, & Mak, 2013; Willett, 2012); and (f) certain auto-immune
disorders (e.g., rheumatoid arthritis, Karlson et al., 2013, Solomon et al., 2003; and lupus,
Hak et al., 2009). Results from the Huertas-Vazquez et al. (2013) study, which used NHS
data, documented potential linkages between schizophrenia and increased risk for CVD
resulting from a neuregulin 1 genetic mutation. Studies using NHS data have additionally
provided support that CVD risk can be reduced by (a) eating a Mediterranean diet
(Crous-Bou et al., 2014; Gu et al., 2015; Hindy et al., 2014); (b) reducing the intake of
foods high in fats and fructose (Stanhope et al., 2013; Willett, 2012); (c) engaging in
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exercise (Archer & Blair, 2011; Du et al., 2013); and increasing coffee intake (Freedman,
Park, Abnet, Hollenbeck, & Sinha, 2012).
Cardiovascular Disease Risk Factors Among Nurses
Nurses are knowledgeable about CVD, yet studies have documented that they are
at risk for CVD (Lang et al., 2012; McElligott et al., 2009). According to the Department
for Professional Employees (DPE, 2012), 91.1% of RNs and 93.4% of licensed practical
nurses were women. The mean age of nurses as of 2011 was 50 years (Nahm et al., 2012).
The high prevalence of female nurses and the aging of nurses increase the likelihood that
individuals in this white-collar profession are at greater risk for CVD compared to those
in other professions (DPE, 2012; McElligott et al., 2009; Nahm et al., 2012). Family
history of CVD is another demographic risk factor (CDC, 2015). Fair et al. (2009), in a
study of CVD risk factors in nurses, found that more than 20% of nurses in the study had
a family history of premature death from CVD. The percentage of nurses with a family
history of early onset CVD was 34.2% in the Puett et al. (2009) study using NHS data.
High rates of CVD risk factors exist among nurses across the health, mental
health, health-related behaviors, and demographic-risk domains, which can negatively
impact people’s health and well-being (ANA, 2015; Baer et al., 2011; Fair et al., 2009;
Khan et al., 2012). A major risk factor for CVD among nurses is obesity (ANA, 2015). In
a study by Louie and Wedell (2014) using NHS data, 60% of acute-care nurses in the
study were obese or overweight. In a recent study by the ANA (2015), the percentage of
nurses who were obese was a disconcerting 70%. Associated with obesity are a sedentary
lifestyle and poor dietary habits (ANA, 2015).
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Across studies examining CVD risk factors in nurses, results showed that, on
average, 11% of nurses have diabetes; higher that the average percentage of 9% for U.S.
adults (Khan et al., 2012; Preventive Cardiovascular Nurses Association, 2008). The
percentage of nurses with hypertension in studies has ranged from approximately 18% to
over 40%, and the percentage of nurses with elevated cholesterol levels has ranged from
15% to 50% (Khan et al., 2012; Lang et al., 2012; Puett et al., 2009). Baer et al. (2011)
and Li et al. (2006), using data from the NHS, concluded that obesity, diabetes,
hypertension, and high cholesterol significantly aligned with increased risk of mortality
due to CVD among nurses.
Pharmacogenetic and Pharmacogenetic Testing
Pharmacogenetics, which “blends components of the disciplines of genetics and
pharmacology,” refers to the study of genetic variations of individuals that affect drug
metabolism (Johnson & Cavallari, 2013, p. 987). The premise of pharmacogenetics is that
genetic variability can results in two types of drug reactions related to pharmacokinetics,
or the effects of a dosage of the drug and pharmacodynamics, or the effects of the drug
itself on the body (Howland, 2012; Johnson & Cavallari, 2013). Pharmacokinetics and
pharmacodynamics assist in the clinical understanding of (a) drug concentration,
metabolism, and clearance; (b) drug dosage needed for clinical affect; and (c) the
likelihood of an adverse drug reaction (Blakey & Hall, 2011; Howland, 2012).
Pharmacogenetic is a prime example of personalized medicine (Johnson & Cavallari,
2013; Scott, 2011). “Personalized medicine entails engagement between patient and
health care provider, identification of relevant genetic variations for implementation,

47
assay reliability, point-of-care decision support, and necessary institutional investments”
(Scott, 2011, p. 987).
Pharmacogenetic research has existed for more than 60 years, with the term
pharmacogenetic coined in 1959. Until the late 1990s, most pharmacogenetic studies,
uncommon in the literature, focused on DNA sequencing to identify patients who might
respond differently to medications (Johnson & Cavallari, 2013; Squassina et al., 2010).
Advances in the understanding of genetics, the growth of specialized technology for
medicine, the high rates of CVD, and the advent of personalized medicine contributed to
the emergence of pharmacogenetic research related to major cardiovascular medications
in the late 2000s (Scott, 2011), with much work conducted on CVD drugs such as
antiplatelet agents, warfarin, statins, beta blockers, diuretics, as well as antiarrhythmic
agents (Kadafour et al., 2009; Musunuru et al., 2012; Roden, 2012; Van Schie et al.,
2012; Verschuren et al., 2011).
The study conducted by Frazier et al. (2005) stressed that knowledge of genetic
components of CVD (such as cardiomyopathy and heart failure) in conjunction with
pharmacogenetics can improve cardiovascular nursing care. Heart failure is the decreased
ability of the heart to fill and to eject adequate blood to the entire body. Cardiomyopathy
is the second highest cause of sudden cardiac death in the United States; the primary
cause of cardiomyopathy is genetic disposition (Frazier et al., 2005). For instance,
patients with ischemic heart disease with genotypes associated with poor prognosis
respond well to statins (Kadafour et al., 2009; Verschuren et al., 2011). Patients with a
gene that encodes angiotensin converting enzymes and β₁-adrenergic receptors respond
less well to cardiovascular drugs (Verschuren et al., 2011).
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Nurses’ Knowledge of Pharmacogenetic Testing
To effectively communicate with patients about pharmacogenetic testing, it is
important that healthcare providers have at least adequate levels of knowledge of
pharmacogenetic testing: “patients demand accurate and timely information … about …
pharmacogenetic testing and what the results mean” (Payne & Annemans, 2013, p. 20).
Results from the minimal body of literature on healthcare providers’ knowledge of
pharmacogenetic testing (e.g., Bannur, Bahaman, Salleh, & Kek, 2014; Moen & Lamba,
2012; Roederer et al., 2012; Stanek et al., 2012) showed that physicians and pharmacists
lack such knowledge. The knowledge of pharmacogenetic testing among nurses is even
less understood.
The body of literature on nurses’ knowledge of pharmacogenetic testing is small
but growing. Some studies (e.g., Dodson, 2011; Dodson & Van Riper, 2011; Haga &
LaPointe, 2013; Haga, O’Daniel, Tindall, Lipkus, et al., 2012) included various
healthcare providers, including nurses, as participants. The focus of the Haga, O’Daniel,
Tindall, Lipkus, et al. (2012) and Haga, Tindall, & O’Daniel (2012) qualitative studies
were to examine differences between primary care and genetics in healthcare
professionals’ knowledge of pharmacogenetic testing specific to CVD. Of the 21
participants, 11 were primary-care providers and 10 were genetics healthcare
professionals. Participants included nurse practitioners, but not nurses, in both groups.
From focus-group data, specific themes emerged surrounding differences between
primary care and genetics healthcare providers’ knowledge of pharmacogenetic testing.
Nurse practitioners conceded their lack of knowledge of pharmacogenetic testing, and did
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so at a greater degree than did primary-care physicians (Haga, O’Daniel, Tindall, Lipkus
et al., 2012; Haga, O’Daniel, Tindall, Mills et al, 2012).
Dodson (2011) conducted a review of the literature on healthcare providers’
knowledge of pharmacogenetic testing that included studies conducted with nurses.
Dodson (2011) reviewed 12 studies, the oldest published in 1999, equally divided across
quantitative and qualitative methodologies, and 50% were conducted in the United States.
Notable findings were that a substantial majority—66% to 84%—of healthcare providers,
including nurses, reported having minimal knowledge of pharmacogenetic testing. No
differences emerged in knowledge between nurses and pharmacists.
Dodson extended this work with a follow-up study (Dodson & Van Riper, 2011)
conducted with 184 healthcare providers, of which 75 were RNs and 35 were nursing
students. The researchers asked participants to respond to a series of open-ended
questions about pharmacogenetic testing, and analyzed responses using content analysis.
Many of the four themes that emerged provided examples as to how the (lack of)
knowledge of pharmacogenetic testing impaired healthcare providers’ patient-centered
practices. The first theme concerned healthcare providers’ negative concerns regarding
pharmacogenetic testing. Decreased knowledge of pharmacogenetic testing often led to
healthcare providers’ perceptions that pharmacogenetic testing itself was inaccurate,
unreliable, or impractical. The second theme concerned the lack of successful integration
of pharmacogenetic testing into general healthcare practices. The lack of knowledge of
pharmacogenetic testing led to increased resistance among healthcare providers to
educate themselves on and increase their knowledge and use of pharmacogenetic testing.
Much of this resistance stemmed from healthcare providers’ perceptions that
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pharmacogenetic testing was too new and novel to be meaningful to their current patient
practices (Dodson & Van Riper, 2011).
The third and fourth themes found in the study by Dodson and Van Riper (2011)
focused on patients, specifically with regard to patient healthcare disparities and potential
harm of pharmacogenetic testing to patients. A majority (80%) of the 75 RNs in the study
noted concerns that, as seen with other medical advances, availability and access to
pharmacogenetic testing would be limited to those who could afford it, thereby
“exacerbating disparity” between high- and low-income healthcare consumers (Dodson
& Van Riper, 2011, p. 536). In turn, the disparity in availability and access to
pharmacogenetic testing may result in “two different standards of care”: one for the
wealthy and one for the poor (Dodson & Van Riper, 2011, p. 536). Aligned with these
disparities was the potential harm of pharmacogenetic testing: healthcare providers
voiced concerns that pharmacogenetic testing could cause more harm than benefit to
patients. Perceptions of harm included (a) increased healthcare costs for patients;
(b) prolonging the life of patients who had very poor quality of life; (c) physician reliance
on testing, resulting in “less vigilance” in monitoring, for example, medication reactions;
and (d) increasing patient distress, anxiety, and fear of genetic conditions or geneticbased diseases (Dodson & Van Riper, 2011).
Fewer studies (e.g., Blakey & Hall, 2011; Godino & Skirton, 2012; Kadafour et
al., 2009; Van Riper et al., 2011) focused exclusively on nurses. Results from these
studies reiterated the lack of knowledge of pharmacogenetic testing among nurses as well
as the possible consequences that may occur as a result of this lack of knowledge. Blakey
and Hall (2011), in a study conducted with British nurses, found that a major challenge
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for nurses was to explain results from pharmacogenetic testing to patients, who required
expert knowledge on genetics and pharmacogenetic; knowledge nurses reported not
having. Results from the Kadafour et al. (2009) study suggested that lack of knowledge
of pharmacogenetic testing may prevent nurses from participating in studies on the topic:
of the 2,038 nurses recruited for the study, only 448 (22%) completed the study.
Moreover, of these 448 nurses, 40% reported being unclear as to the clinical benefits of
pharmacogenetic testing (Kadafour et al., 2009). The most concerning result was that the
average pharmacogenetic-testing-knowledge score among nurses was 40% (Kadafour et
al., 2009).
Although not examining nurses’ knowledge of pharmacogenetic testing per se,
Godino and Skirton (2012) conducted a systematic review of the literature on nurses’
knowledge of genetics. Godino and Skirton’s review of the literature shared similarities
to previous literature reviews discussed in a chapter by Edwards (2009) and Dodson
(2011). Godino and Skirton retrieved only six relevant studies, and even with this small
number of articles, considerable variability existed in location (e.g., three studies were
conducted in the United States, three each in Scotland, Singapore, and Canada). The
review was, however, strengthened by its focus on quantitative descriptive cross-sectional
studies that used nurse participants, had the singular aim of providing descriptions of
nurses’ level of knowledge on genetics, and measured nurses’ perceived knowledge of
genetics. Results from Godino and Skirton’s study replicated previous findings in that,
across studies, nurses’ knowledge of genetics was poor.
The most comprehensive study on nurses’ knowledge of pharmacogenetic was
conducted by Van Riper et al. (2011) with 560 RNs. Although the initial intent of the
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study was to determine nurses’ knowledge of pharmacogenetic as it pertained to CVD,
the study expanded to include other pharmacogenetic topics. Results from the Van Riper
et al. study reiterated those found in previous studies (e.g., Dodson, 2011, 2014, 2015;
Kadafour et al., 2009). A third (33%) of nurses reported their understanding of
pharmacogenetic as poor and 44% reported their knowledge as fair. Most concerning was
the performance on tests that gauged knowledge of pharmacogenetic testing: the mean
score of the 10-item test was 60.3%, equivalent to a grade of D. Only 33% of nurses
correctly responded with true when answering the statement, “genetic determinants of
drug response change over a person’s lifetime” (Van Riper et al., 2011, p. 7).
Nurses’ Attitudes about Pharmacogenetic Testing
One important factor influencing a successful implementation of pharmacogenetic
testing is nurses’ attitudes toward it: these attitudes often determine their behavior in
caring for the patients (Chadwell, 2013; Dodson, 2011, 2014, 2015). The literature on
nurses’ attitudes toward pharmacogenetic testing is somewhat less robust than the
literature on nurses’ knowledge, with much of the empirical work done by Dodson (2011,
2014, 2015) and Haga and colleagues (Haga, Kawamoto, Agans, & Ginsburg, 2011;
Haga & LaPointe, 2013; Haga & Mills, 2015; Haga, O’Daniel, Tindall, Lipkus et al.,
2012, ; Haga, O’Daniel, Tindall, Mills et al. 2012; Mills & Haga, 2013). Despite the
dearth of such studies, results from these studies have consistently documented that
ethical issues and advantages of testing are central concerns among nurses (Dodson,
2011, 2014, 2015; Haga et al., 2011; Haga & LaPointe, 2013; Haga & Mills, 2015).
These two attitudinal issues are discussed in the following sections.
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Pharmacogenetic testing: Ethical issues. In the era of the Affordable Care Act,
patient-centered care, and genomic medicine, numerous issues surround pharmacogenetic
testing (Dodson, 2011). In Dodson’s (2011) review of the literature, eight of the 11
articles reported nurses’ ethical concerns about testing; the most frequent being
employment and insurance discrimination based on the individual’s pharmacogenetic
testing profile. Ethical issues emerged as a primary issue in the Van Riper et al. (2011)
study; with 47% of the nurses expressing concern that pharmacogenetic testing would
result in employment and insurance discriminatory practices. Ethical issues regarding
pharmacogenetic testing have been so concerning to nurses and other healthcare
providers that in numerous studies, nurses and other providers have voiced a need for
informed consent for this type of testing (Bartlett, 2011; Dodson, 2011, 2014, 2015). As
stated by Bartlett (2011), “patients (accepted) pharmacogenetic testing (when) their rights
to consent and privacy were fully protected” (p. 27).
At issue is whether patients’ genetic information would be given to their
employers, health-insurance representatives, and other agencies and individuals (Bartlett,
2011). According to Haga and Burke (2008) and Haga et al. (2011), pharmacogenetic
testing does not have comprehensive reimbursement of companion diagnostics, even
when recommended by the Food and Drug Administration. Health-insurance
representatives are quite reluctant to reimburse for pharmacogenetic testing as they claim
that its clinical usefulness coupled with knowledge of pharmacogenetic is very
questionable (Haga & Burke, 2008; Haga et al., 2011; Haga & LaPointe, 2013). For
instance, for warfarin, a CVD medication, individuals with a particular enzyme activity
called CYP2C9 need a reduced dose and require constant monitoring of their blood level
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to prevent bleeding (Bannur et al., 2014). In view of this problem, the Food and Drug
Administration mandated genotyping for all patients prior to issuing a warfarin
prescription; this poses significant challenges when insurers do not reimburse for the
companion testing (Haga et al., 2011).
Despite the benefits associated with pharmacogenetic testing, doctors, nurses,
pharmacists, and other healthcare professionals face ethical dilemmas regarding who
should be tested and the appropriateness of testing in conjunction with treatment options
(Calzone et al., 2010). Shin et al. (2009) maintained that the lack of availability of
pharmacogenetic testing for patients and the high cost, as well as the lack of
reimbursement, all impede the introduction of pharmacogenetic testing in the healthcare
arena. Only 8% of laboratories in the United States can competently perform the
pharmacogenetic tests needed for patient care, which eventually caused a much longer
turnaround time for needed test results (Calzone et al., 2010). Because turnaround time
might take several days or weeks, the safety and well-being of patients is compromised if
the test result is needed immediately for clinical decision making, as in the case of
warfarin dosing for anticoagulation purposes. The average cost of pharmacogenetic
testing ranges from $250 to $500. Insurers tend to reimburse only a few of these tests, as
the majority of them are considered experimental (Calzone et al., 2010).
Pharmacogenetic testing: Advantages. The second theme seen in the literature
on nurses’ attitudes about pharmacogenetic testing pertained to its perceived advantages.
The most frequently reported advantage reported by nurses was the reduced likelihood of
patient adverse reactions to drugs (Dodson, 2011, 2015). Haga et al. (2011) and Haga and
Mills (2015) reported similar findings. Van Riper et al. (2011) also examined attitudes
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toward pharmacogenetic testing among nurses and their results were quite similar to
those found by Dodson (2011). In contrast to Dodson (2011), who reported one primary
advantage of pharmacogenetic testing (i.e., reduced adverse reactions to medications),
Van Riper et al. elicited additional advantages from nurses: (a) decreased drug reactions
in general, (b) decreased drug reactions to CVD medications, (c) reduced time needed to
titrate a CVD medication, and (d) decreased costs of pharmacogenetic-derived
medications.
A criticism of the research on attitudes toward pharmacogenetic testing, as well as
the research on knowledge, is that most studies used a descriptive cross-sectional
research design or were reviews of literature, resulting in a gap in the literature
concerning antecedents of nurses’ knowledge of pharmacogenetic testing. In Dodson’s
(2014) seminal study, the researcher examined work-based, demographic, and personality
antecedents of pharmacogenetic testing knowledge and attitudes of 368 oncology acutecare nurses in North Carolina. Results showed that various factors influenced
pharmacogenetic testing knowledge and attitudes among acute-care nurses. Although
experience and exposure to pharmacogenetic testing led to increased knowledge and
acceptance of pharmacogenetic testing among nurses, nurses’ personality factors of
openness to experience, conscientiousness, and agreeableness, and their “desire for
innovation” were additional predictors of higher levels of acceptance of pharmacogenetic
testing (Dodson, 2014, p. e68).
Summary and Conclusions
The purpose of Chapter 2 was two-fold. The first purpose was to provide an
extensive review of the study’s guiding theory: the Rosenstock et al. (1974) HBM. In
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addition to an explication of the theoretical components of the HBM were discussions of
the HBM in nursing research and the present study’s application of the HBM. The second
purpose of the chapter was to provide a comprehensive review of the literature with
regard to nurses’ perceptions of their own risk for CVD as well as nurses’ knowledge and
attitudes toward pharmacogenetic testing. The literature review revealed that few studies
have been conducted with acute-care nurses about their perceived risk for CVD; the
Jones et al. (2006) study was the most informative study on this topic to date. Studies
examining nurses’ knowledge and attitudes toward pharmacogenetic testing were, for the
most part, descriptive studies (e.g., Dodson, 2014, 2015; Haga, O’Daniel, Tindall, Lipkus
et al., 2012; Haga, O’Daniel, Tindall, Mills et al. 2012; Haga, Tindall, et al., 2012; Van
Riper et al., 2011) or reviews of the literature (e.g., Dodson, 2011; Godino & Skirton,
2012; Verschuren et al., 2011). Studies concerning nurses’ attitudes toward
pharmacogenetic testing (e.g., Dodson, 2011, 2015) highlighted concerns about
pharmacogenetic testing, such as ethical and financial reimbursement issues, as well as
advantages, including reduced likelihood of adverse reactions to medications among
patients.
The review of the literature uncovered gaps in the literature concerning
knowledge and attitudes of acute-care nurses regarding pharmacogenetic testing. A
primary gap found was the lack of studies examining antecedents of perceived risk for
CVD and knowledge and acceptance of pharmacogenetic testing for CVD. Dodson’s
(2014) seminal work provided much of the foundation for the present study, as it was the
only study that examined work-based, demographic, and personality antecedents of
pharmacogenetic testing knowledge and of attitudes in acute-care nurses. The present
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study addressed this concerning gap in the literature. The implications of prior research
on this research have been fully addressed. The study methodology, including the
research design, sampling issues, study variables and their operational definitions, and
data collection and analysis procedures are the focus of Chapter 3.
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Chapter 3: Methodology
In this quantitative study, using a correlational, cross-sectional design and
conducted with licensed acute-care nurses in Atlanta, Georgia, I had three goals aligned
with the HBM (Rosenstock, 1974). The first goal was to determine if nurses’ gender,
highest level of education, and years of experience significantly related to their perceived
risk for CVD. The second goal was to determine if nurses’ gender, highest level of
education, and years of experience significantly related to their knowledge of
pharmacogenetic testing for CVD. The third and last goal was to determine if a
significant association arose between nurses’ perceived risk for CVD and their
acceptance of pharmacogenetic testing for CVD.
The purpose of this chapter is to provide a summary of the research design and
methodology. First, I review the research design and rationale in this chapter, and
continue with an overview of the population and sample, sample size, and sampling
procedures. I then comprehensively discuss the study methodology, inclusive of the
instruments used in the study, data-collection procedures, and data analysis. Upon
completion of the methodology discussion, I provide a summary of instrument reliability
and validity and outline the ethical procedures of the study. The chapter ends with a
summary and conclusion section.
Research Design and Rationale
The study was quantitative in nature and used a cross-sectional research design.
The quantitative approach was appropriate for this study, as I statistically analyzed
numerical data from self-report surveys for hypothesis testing (Stangor, 2014). The
quantitative approach was guided by the scientific method, with a goal of objectivity.
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This study was correlational, examining relationships between variables, and crosssectional, as data accrued at one point in time (Stangor, 2014). This study was not
appropriate for a quantitative causal-comparative research design as it focused on
relationships between independent and dependent variables and does not examine group
differences on a dependent variable. As this was not a study with intervention and control
groups, quantitative quasi-experimental and experimental research designs were not
applicable (aligned with Treiman, 2014). As this was not an experimental quantitative
study, causality could not be proven (as averred by Kleinbaum, Kupper, Nizam, &
Rosenberg, 2013).
Methodology
Population and Sample
Study participants, who represented the population of acute-care nurses in the
United States, were registered acute-care nurses with active licenses working in acute
hospital settings in Atlanta, Georgia. The sample frame—the group of acute-care nurses
who had a chance to participate in the study—included all registered acute-care nurses in
Atlanta, Georgia. As of 2014, the number of licensed acute-care nurses in Georgia was
155,607 (Stephens, 2015). Approximately 7.5% (n = 11, 670) of these licensed nurses
worked in acute-care settings in the city of Atlanta (Stephens, 2015). I retrieved workcontact information for these acute-care nurses from the database of the Georgia Board of
Nursing with permission of the Board, and I informed all registered acute-care nurses
who work in acute-care settings in Atlanta of this study and invited them to participate.
I gave every RN working in an acute-care setting in Atlanta Georgia an equal
opportunity to participate in this study. However, I did not randomly select acute-care
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nurses for the study; that is, although the study was open to all acute-care nurses who met
study criteria, acute-care nurses themselves chose whether to participate in the study.
Thus, participants comprised a nonprobability purposive sample; being acute-care nurses,
they were a subset of all acute-care nurses.
Sample Size
In accordance with recommendations from Kasiulevičius, Šapoka, and
Filipavičiūtė (2006) and Charan and Biswas (2013), I conducted an epidemiological
power analysis for a cross-sectional descriptive study. The power analysis mathematical
formula for a cross-sectional descriptive study is Z1-α/22 p (1- p)/d2, where Z1-α/22 is the
normal variate of 1.96 for significance (p) set at < .05, p is the prevalence rate of the
health issue in the population; and d is “absolute error or precision” as indicated by
confidence levels, typically set at 95% (or +/- 5% confidence limits; Charan & Biswas,
2013, p. 122). Power analyses for epidemiological descriptive cross-sectional studies may
also include a design effect (DE), which is a ratio of the actual variance using the selected
sampling method to the possible variance using random sampling (Kasiulevičius et al.,
2006). However, DE is a concern when using clustered data, which this study did not use
(Kasiulevičius et al., 2006).
I conducted the power analysis using an online epidemiological power analysis
calculator (http://www.openepi.com/SampleSize/SSPropor.htm). I set the prevalence rate
to 30%, based on rates of CVD among Caucasian middle-aged women in the United
States (AHA, 2015; Go et al., 2013; WHF, 2014), the confidence level to 95%, and left
the DE at the default value of 1.00, as the study data were clustered (Kasiulevičius et al.,
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2006). Results from the power analysis determined that a sample size of N = 228 was
required for the study.
Sampling Procedure
I obtained a purposive sample of N = 228 licensed nurses without a CVD
diagnosis working in acute-care units at Atlanta metropolitan-area hospitals. With Board
permission, I retrieved work-contact information of these acute-care nurses from the
database of the Georgia Board of Nursing. I sent out a study-invitation email to all acutecare nurses who met study criteria. In this email, I explained the purposes, nature, length,
and intent of the study; this information was summarized in a study-information letter
attached to the email. I included a link to the study’s Survey Monkey survey in the text of
the email and in the study-information letter. The email also contained language that
reviewed the informed consent procedure and included, as an attachment, the study’s
informed consent form. The informed consent form stated that participation in the study
was voluntary and participants could stop answering the survey at any time without
penalty. I summarized the risks and benefits of participating in the study in the consent
form, and provided my contact information and the contact information of the
Institutional Review Board of Walden University.
The email ended with a request for interested participants to send me an email to
schedule a phone call to discuss the study in detail, should they want more information
about the study. Participants had the ability to choose to forgo the phone call and click on
the Survey Monkey survey link to take the survey online. Before they could answer the
survey, they first had to read the consent form online and then click “yes” to three
statements: (a) they understood their rights as a human subject in this research study,
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(b) their questions or concerns about the study or their role in it were answered; and
(c) they provided informed consent to participate in the study. If participants clicked “no”
to any of these statements, they were automatically directed out of the survey link site
and could not access it again if using the same computer.
Participants who wished to know more about the study and their role in the study
could email me to schedule a phone call. I answered any questions from potential
participants regarding the study during this phone call. Following this call, I again sent
(through email) the Survey Monkey study link for participants to complete the study
survey. Participants also had the option to click on the Survey Monkey survey link in the
original email (and attached document) I sent to them. Participants had 3 weeks to answer
the survey. The Survey Monkey site that contained the data was accessible only to me, as
I had registered with Survey Monkey and could only access the data by providing my
user name and password.
Instrument and Operationalization of Constructs
In this section, I first present the instruments used for the study’s independent and
dependent variables. Following the description of instruments are descriptions on the
measurement of the independent variables of gender, years of practice, and years of
education and the study covariates.
Independent and dependent variables: Perceived risk for cardiovascular
disease. Perceived risk for CVD was both an independent and dependent variable in this
study, measured using the Perception of Risk of Heart Disease Scale (PRHDS; Ammouri
& Neuberger, 2008, see Appendix B). The HBM was the theoretical framework for the
development of the PRHDS (Ammouri & Neuberger, 2008), as health-risk perceptions
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were influenced by the individual’s demographics (e.g., age, education level, and gender),
psychological factors (e.g., self-concept, worldview, and cultural identity), and contextual
factors (e.g., media reports of CVD risk factors and availability of social resources). The
PRHDS measures the continuum of perceived risk of heart disease from thinking that one
has little risk for CVD (e.g., “My lifestyle habits do not put me at risk for heart disease”)
to dread risk for CVD, or that one’s risk for CVD is definitive (“I feel sure that I will get
heart disease”; Because the PRHDS measures perceived risk for CVD on a continuum, it
was treated as an interval-coded scale (Ammouri & Neuberger, 2008).
The PRHDS has 20 items scored using a Likert-type scale from 1 = strongly
disagree to 4 = strongly degree (Ammouri & Neuberger, 2008). Of the items, 12 are
reverse scored and should be recoded before summing items to create the full scale.
Scores on the PRHDS can range from 20 to 80 points with a higher score denoting higher
levels of perceived risk for heart disease (Ammouri & Neuberger, 2008).
A panel of 10 survey development experts assessed the content validity of the
PRHDS, examining items “for clarity, homogeneity of content, and representativeness of
the concept domain” (Ammouri & Neuberger, 2008, p. 87). Once the experts gave their
approval for the survey, Ammouri and Neuberger (2008) confirmed the content validity
of the PRHDS by conducting a confirmatory factor analysis that showed the one-factor
PRHDS explained 53% of the variance. There are significant associations between the
PRHDS and scale of health responsibility, physical activity, spiritual growth, and stress
management, confirmed criterion-related validity of the PRHDS with rs ranging from .21
to .39, p < .01. The inter-item reliability for the PRHDS had a Cronbach’s alpha of .80
and the 2-week test–retest reliability is .69 (Ammouri & Neuberger, 2008).
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Dependent variable: Knowledge of pharmacogenetic for cardiovascular
disease. I assessed knowledge of pharmacogenetic testing for CVD, which was a
dependent variable in this study, using the Pharmacogenomics Knowledge Scale (PKS;
Bannur et al., 2014, see Appendix C). Bannur et al. (2014) developed the PKS to inform
the professional practice of CVD pharmacogenetic testing in healthcare settings, arguing
that healthcare providers must demonstrate “the skill to translate patient’s genetic history
for optimum drug therapy” to prevent or delay CVD (p. 40). The ratio-coded PKS
comprised five items scored as 1 = true and 0 = false; three items are true and two items
are false. An example item is “Pharmacogenetic testing is currently available for most
heart disease medications” (scored as a false item). The total PKS scale score is a sum of
the number of correct items divided by five to obtain a percentage score, which can range
from 0% to 100% (Bannur et al., 2014).
The PKS went through a rigorous two-panel review process to determine its
content validity. Five researchers specializing in the field of pharmacogenetic testing sat
on the first panel, and the second panel included 10 pharmacists and physicians (Bannur
et al., 2014). The two panels confirmed the content validity of the PKS. Bannur et al.
(2014) validated the PKS in a study conducted with 503 healthcare professionals.
Significant relationships between pharmacogenetic testing knowledge and genetics
knowledge (at r = .27, p < .01) provided support for criterion-related validity. Statistical
results supported the discriminant validity of the PKS, showing significantly higher mean
scores among pharmacists and physicians having more years of practice than those
having fewer years of practice, χ² (4, N = 1,500) = 78.79, p < .001, and pharmacists and
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physicians working in urban healthcare settings versus rural healthcare settings, χ² (2,
N = 1,500) = 7.48, p = .024 (Bannur et al., 2014). The PKS scores dichotomously.
Dependent variable: Acceptance of pharmacogenetic testing for
cardiovascular disease. I used the Attitudes Toward Pharmacogenomics Scale (APS;
Bannur et al., 2014) to measure acceptance of pharmacogenetic testing for CVD, which
was a dependent variable in this study. Bannur et al. (2014) developed the APS to address
the lack of awareness of CVD pharmacogenetic testing among healthcare providers. The
APS is a Likert-coded scale comprising eight questions that assess the degree to which
healthcare providers feel comfortable with and accept pharmacogenetic testing for CVD
for their patients. An example item is, “How comfortable would you be having genetic
information incorporated into the determination of your patient’s initial warfarin dose?”
The response coding for APS items range from 1 = very uncomfortable to 5 = very
comfortable. Summing the scores from each of the eight items provides a total APS
score; scale scores can range from 8 to 40 with a higher score denoting higher levels of
comfort/acceptance (Bannur et al., 2014).
The APS went through a rigorous two-panel review process to determine its
content validity. Five researchers specializing in the field of pharmacogenetic testing sat
on the first panel, and the second panel included 10 pharmacists and physicians (Bannur
et al., 2014). These two panel reviews confirmed the content validity of the APS (Bannur
et al., 2014). A study conducted with 1,500 healthcare professionals validated the APS.
Significant relationships between acceptance of pharmacogenetic testing and genetics
knowledge (r = .17, p < .05) provided support for criterion-related validity. Findings
showing significantly higher mean scores among cardiologists, compared to other types

66
of physicians, F(2, 500) = 7.80, p = .001, and healthcare providers working at pharmacies
or medical schools, compared to healthcare providers working in other settings (e.g.,
public/private hospital, private practice), F(2, 500) = 2.71, p = .041 supported the
discriminant validity of the APS. The inter-item reliability of the APS is .76 (Bannur et
al., 2014).
Independent variable: Gender. I measured the independent variable of gender
with a dichotomously coded question: “What is your gender?” The response coding was
0 = female and 1 = male.
Independent variable: Years of education. I measured the independent variable
of years of education with an ordinal-coded item: “What is the highest educational degree
you have completed?” Responses scored were 1 = Associates’ degree, 2 = Bachelors’
degree, 3 = Master’s degree, and 4 = Doctorate degree.
Independent variable: Years of practice. I measured the independent variable
of years of practice with an open-ended question: “How long have you been in your
current position?” The question aimed to obtain information on years of practice, a ratio
variable.
Covariate: Health factors related to estrogen. In the survey, I asked
participants if they (a) had a hysterectomy, (b) were postmenopausal, (c) were on
hormone-replacement therapy, or (d) took birth-control pills. If participants answered
“yes” to one or more of these items, they were categorized as 1 = have health factor
related to estrogen. If participants answered “no” to all of these questions, they were
categorized as 0 = have no health factors related to estrogen.
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Covariate: Medication-related cardiovascular disease risk. I asked acute-care
nurses if they took any medications(s) that can influence CVD risk; that is, medications
used for other health conditions but that increased CVD risk (e.g., birth control,
prednisone) or decreased CVD risk (e.g., diuretics). I provided participants a list of
medications that had associated CVD risk and asked them to select the medications they
were currently prescribed. I categorized participants who did take such medication(s) into
the 1 = have medication-related CVD risk group, whereas participants who did not take
such medication(s) were categorized into the 0 = do not have medication-related CVD
risk group.
Data-Analysis Plan
I transferred the Survey Monkey data file directly into an SPSS 22.0 data file,
kept on a jump drive. Once I downloaded the data into an SPSS data file, I reviewed the
data set and corrected for entry mistakes, missing data, and outliers. If a case was missing
>= 50% or if a case had >= 25% of data missing not at random (MNAR), it was removed
from the data set (aligned with Stangor, 2014). I determined univariate outliers using the
SPSS outlier function, and winsorized identified outliers (i.e., replaced them with the next
lowest or highest value. I detected multivariate outliers with the SPSS Mahalanobis
distance function. I calculated the inter-item reliability for pharmacogenetic testing
knowledge and acceptance scales with Cronbach’s alpha; an acceptable Cronbach’s alpha
is >= .70 (in line with Stangor, 2014). I computed study scales.
Prior to performing the regression analyses for hypothesis testing, I conducted
descriptive and preliminary inferential statistical analyses, reporting frequencies and
percentages for the demographic variables and covariates and the means, standard
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deviations, and minimum and maximum scores for the study scales (i.e., PRHDS, PKS,
and APS). I conducted specific statistical tests to determine and address violations of
assumptions for regression analyses (as suggested by Stangor, 2014). I determined the
assumption of normality in the distribution of scale scores by calculating scale skewness
scores (i.e., skewness value divided by skewness standard error). A skewness value that
is < 2.00 indicates that the multivariate normality assumptions have been met.
Homoscedasticity is an assumption that pertains to the equality of residual errors (i.e.,
errors are constant), tested by plotting residuals using scatterplots. If the data points
display an equivalent distribution above and below the horizontal line, this assumption
has been met (Stangor, 2014). Multicollinearity, another assumption for linear regression
analyses, refers to a very high correlation among independent variables to the extent that
they are measuring the same construct. Variance inflation factors (VIFs) for each
independent variable association determine multicollinearity. This assumption is met if
VIFs are < 4.00 (Stangor, 2014).
For this dissertation, I proposed seven research questions. For Research Questions
1 through 3, I conducted one HMLR. I entered the covariate of take medication that
affected CVD risk in the first model (step) of the HMLR, as it significantly related to the
dependent variable of perceived risk for CVD. I entered the independent variables of
gender, years of education, and years of experience together in the second model (step) of
the HMLR. Perceived risk for CVD was the dependent variable for these first three
research questions.
For Questions 4 through 6, I conducted a MLR; I did not include the two variables
of take medication that affects CVD and estrogen-related health conditions in analyses as
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they did not significantly correlate with the dependent variable of knowledge of
pharmacogenetic testing for CVD. I entered the independent variables of gender, years of
education, and years of experience collectively in the first and only model (step) of the
MLR. The dependent variable for the fourth through sixth research questions was
knowledge of pharmacogenetic testing for CVD.
I conducted an HLR for the seventh and last research question. Knowledge of
pharmacogenetic testing for CVD significantly aligned with acceptance of
pharmacogenetic testing for CVD and thus, I entered it as a covariate in the first model
(step) of the HLR, followed by the independent variable of perceived risk for CVD in the
second model (step) of the HLR. Perceived acceptance toward pharmacogenetic testing
for CVD was the dependent variable for the seventh and last research question.
The decision to enter independent variables collectively versus singly would have
required six HMLRs/MLRs, which would have decreased the power of the study,
resulting in an increased likelihood of committing a Type I error (i.e., rejecting the null
hypothesis when it should have been retained). Entering the independent variables
together on one model (step) of the HMLR/MLR increased the statistical power of the
analysis. Further, these analyses allowed determination of which of the three independent
variables were most influential and also informed me “about the structure by which
multiple predictors simultaneously” related to the dependent variable (Stangor, 2014,
p. 341).
I determined statistical significance of the HMLR models by a significance level
of p < .05 (as suggested by Kleinbaum et al., 2013). Results included the overall F- and
p-values for the two models, and determined the model effect size by the model R2
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(Kleinbaum et al., 2013). Results for the individual predictors included the predictors’
standardized beta weights (β) and p-values (Kleinbaum et al., 2013).
Instrument Reliability and Validity
Instrument reliability refers to the degree to which an assessment tool produces
stable and consistent results across times (test–retest reliability), observers (interrater
reliability), and instrument items (inter-item reliability; Stangor, 2014). Conducting test–
retest reliability was beyond the scope of this study, and the uses of self-report
instruments precluded the need to conduct interrater reliability (according to Stangor,
2014). The instruments used in this study demonstrated sound inter-item reliability.
Nonetheless, I calculated the inter-item reliability coefficients by computing Cronbach’s
alphas for the study instruments. Cronbach’s alphas that are .70 or higher are acceptable
and Cronbach’s alphas that are greater than .90 are deemed excellent for inter-item
reliability (Stangor, 2014).
Instrument validity is the degree to which a test measures what it is purported to
measure (Stangor, 2014). Of the different types of instrument validity, content validity
concerns the degree to which the items in an instrument measure a desired construct.
Expert panels often determine content validity of an instrument when considering
nonstatistical approaches, and exploratory of confirmatory factor analyses when using
statistical approaches. Discriminant validity refers to the ability of an instrument to detect
and measure differences between two or more groups that should demonstrate differences
(Stangor, 2014). For example, as stated previously, the discriminant validity of the PKS
was demonstrated by significantly higher mean scores between pharmacists and
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physicians who had more years of practice than their counterparts who had fewer years of
practice (Bannur et al., 2014).
Criterion-related validity refers to the degree to which a scale score correlates
with a score on an instrument that measures the same or similar construct (Stangor, 2014).
As noted previously, the APS (Bannur et al., 2014) demonstrated criterion-related
validity by significantly correlating with a test of genetics knowledge (r = .17, p < .05;
Bannur et al., 2014). Psychometric studies confirmed the validity of the study scales,
leaving no need to conduct validity testing of instruments that have already been shown
to be valid.
Study Validity
Three types of validity in quantitative research studies pertain to study limitations
in research methodology and design: (a) internal validity, or the degree to which it can be
stated that the observed effects on the dependent variable(s) is due to independent
variables and not to unmeasured confounding variables; (b) external validity, or the
ability to generalize study results to the population or other samples, settings, and times;
and (c) construct validity, or how well a study instrument operationally captures the
constructs under study (Jackson, 2015). Quantitative studies have threats to internal,
external, and construct validity, but these differ according to the type of quantitative
research design employed in the study (Jackson, 2015).
Threats to Internal Validity
Threats to internal validity are participant or study factors that compromise the
ability to state that dependent variable effects were the result of the independent variable
(Jackson, 2015). Threats exist to the internal validity for associational quantitative studies,
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the primary ones being (a) confound bias, (b) self-selection bias, (c) social-desirabilityresponse bias, and (d) reverse causation (Jackson, 2015). Confound bias, the “third
variable problem,” concerns the inability to conclude that dependent-variable effects are a
result of the independent variable, due to an unmeasured extraneous variable that
significantly aligned with the independent and dependent variables (Armistead, 2014,
p. 2). Covariate analysis is a recommended technique to control for confounds bias
(Armistead, 2014). In the present study, two covariates were health factors related to
estrogen and medication-related CVD risk.
Self-selection or volunteer bias occurs in studies that rely on a convenience
sample rather than on random selection of study participants; participants who volunteer
for a study tend to differ in “relevant clinical characteristics” from those who do not
participate in a study (Tripepi, Jager, Dekker, & Zoccali, 2010, p. 98). Examinations of
the self-selection bias in healthcare research has shown that study volunteers tend more
likely to be women and have high levels of education (Tripepi et al., 2010). As these two
factors were variables in this study, I considered this bias when analyzing, interpreting,
and reporting study data.
Social-desirability-response bias, the tendency of study participants to provide
answers to survey items that are socially acceptable irrespective of the truth, is an issue in
associational studies using self-report instruments (Stangor, 2014). Social-desirabilityresponse bias is more likely to occur when researchers ask participants sensitive
questions, such as questions about their weight, health and mental health problems, and
attitudes toward coworkers and supervisors (Chung & Monroe, 2003; Edmonds &
Kennedy, 2012). I considered the study variables of gender, level of education, and years
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of practice to be unthreatening as they are questions often asked in daily settings. It was
unlikely that nurses found the knowledge and attitudes toward pharmacogenetic testing
for CVD to be threatening or sensitive, as these questions pertained more to their skill set
than to personal aspects of their life. Of all study variables, perceived risk for CVD may
have been the variable that was most impacted by this bias: participants may have felt
that, as nurses, they should not be at risk for CVD and may have downplayed their actual
risk. Some evidence exists that social-desirability bias is less likely to occur in studies
that use online-survey formats due to the perceived social distance between study
participants and researcher (Chung & Monroe, 2003; Stangor, 2014). The informedconsent process, wherein I informed participants that their survey responses were
confidential and anonymous, may have also reduced social-desirability bias (as suggested
by Stangor, 2014).
A final threat to internal validity for correlational studies is reverse causation,
which concerns the inability to determine temporal precedence of variables (Jackson,
2015). Genders, level of education, and length or practice were, in this study, immutable
variables that could not be changed by or result from a dependent variable. The only
research question that reverses causation might have influenced was the seventh question
pertaining to perceived risk for CVD and attitudes toward pharmacogenetic testing:
participants’ attitude toward pharmacogenetic testing may have influenced their
perceived risk for CVD. However, as these variables measured disparate constructs, the
risk of reverse causation diminished. The use of HMLR analyses rather than bivariate
correlation analysis further minimized this threat (Jackson, 2015).
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Threats to External Validity
External validity pertains to the ability to generalize study results beyond the
study sample to the population (or other samples), to other points in time, and to other
settings (Jackson, 2015). The external validity of a study depends greatly on the degree to
which study participants represent the population. Convenience sampling reduced the
external validity of the present study, and generalizations of results from this study are
limited (aligned with Jackson, 2015). Results from this study cannot be generalized to
acute-care nurses who work in outpatient settings, critical care, primary care, public
health departments, doctor’s offices, or other nonhospital clinical milieus. Furthermore,
results from this study cannot be generalized to registered acute-care nurses working in
other locations in the United States, nurse assistants, or acute-care nurses who have CVD.
Threats to Construct Validity
Construct validity pertains to the degree to which an instrument measures the
construct it is intended to measure (Houghton, Hunter, & Meskell, 2012). One threat to
construct validity that was a concern in this study was the inadequate explication of
constructs, which concerned the incorrect or inexact operationalization of study
constructs. The measures used in this study have sound construct validity, minimizing the
threat of inadequate explication of constructs. Another threat to construct validity is
monomethod bias, which is the use of a single measure of a construct in a study
(Houghton et al., 2012). This study was limited by this bias, and conclusions from results
are legitimate only in relation to the specific operationalization of the variables of
perceived risk for CVD and knowledge and acceptance of pharmacogenetic testing for
CVD.
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Ethical Considerations
Ethics should be the foundation of any research study, but are especially
important in a study that involves the use of human subjects (Stangor, 2014; National
Institutes of Health Approval No. 894379, see Appendix D). I followed the ethical
procedures outlined by The Institutional Review Board of Walden University (approval
number is 03-11-16-0172642 and it expires March 10, 2017.), which had ultimate
approval of this research project prior to data collection, to ensure participants were fully
protected. Participants in this study had to review and agree to informed consent,
acknowledge they understood their rights as human subjects in research studies, and
confirm that any questions they had were answered. They were required to click “yes” to
denote their agreement to statements that (a) they gave consent to participate in the study;
(b) they understood their rights as human subjects in research; and (c) if they had any
questions, these were answered to their satisfaction. “No” responses resulted in a
termination of the survey, which participants could no longer access.
Other study procedures provided additional ethical assurances. Due to the blind
recruitment and participation process, I had no knowledge as to who completed the study.
The data were confidential and anonymous. I treated the study data and material in an
ethical manner. I was the only person with access to the Survey Monkey survey link,
survey site, and data. Once the study was completed, I deleted the Survey Monkey files
from the Survey Monkey server. I kept data on a jump drive (not a computer hard drive),
stored in a secured and locked file cabinet in my home office. Study paper documents and
the jump drive will be destroyed after 3 years.
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Summary
Describing acute-care nurses’ CVD risk-factor awareness and knowledge of
pharmacogenetic testing is quite crucial in developing interventions for CVD risk among
acute-care nurses. Because acute-care nurses are at the forefront of health promotion and
disease prevention, it is very important for them to observe healthy behaviors and to
educate their patients to perceive the severity of CVD risk. I wanted to know if acute-care
nurses’ CVD awareness significantly impacted healthy behavior such as smoking
cessation, healthy eating habits, regular physical activity, maintaining a healthy weight,
and blood pressure and cholesterol screening habits. In Chapter 4, I discuss the study
findings.
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Chapter 4: Results
Researchers have documented a paradox between actual risk and perceived risk
for CVD among nurses: nurses do not perceive themselves as being at risk for CVD
despite often having numerous risk factors for this disease (Hörnsten et al., 2014; Jones et
al., 2006). This lack of congruence may not only impair the health and work behaviors of
nurses, but may also influence their cognitions and attitudes toward CVD-related
practices, such as pharmacogenetic testing for CVD (Chan & Perry, 2012). The
knowledge base among nurses of pharmacogenetic testing, as well as the acceptance of
such testing, is furthermore limited as a result of the newness of such testing and the
controversy that surrounds it such as the confidentiality of the test results (Johnson &
Cavallari, 2013; Verschuren et al., 2011). Nurses’ lack of perceived risk of CVD, lack of
knowledge of pharmacogenetic testing for CVD, and limited acceptance of
pharmacogenetic testing for CVD may influence their nursing practices, interactions with
patients, and the types of information and knowledge they share with patients (Dodson,
2011, 2015; Moen & Lamba, 2012). Ultimately, patients’ health and well-being is at
stake (Moen & Lamba, 2012).
The purposes of this study were three-fold. The first purpose was to examine if
nurses’ highest level of education, years working as RNs, and gender significantly
influenced their perceived degree of risk for CVD. The second purpose was to examine if
these three factors significantly influenced their reported level of knowledge of
pharmacogenetic testing for CVD. The third and final purpose of this study was to
determine if nurses’ perceived degree of risk for CVD significantly influenced their
reported level of acceptance of pharmacogenetic testing for CVD.
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The purpose of this chapter is to present and discuss the results of regression
analyses (HMLR, MLR, and HLR) conducted for hypothesis testing. The chapter opens
with a review of the data-collection procedures, including the time frame in which the
data collection occurred and the representativeness of the study sample. This section
provides substantial attention to response rates. The chapter continues with a presentation
of the descriptive information of study-participant variables, including demographic and
health factors. I then discuss the results of the study, beginning with a review of study
variables including scale construction, descriptive statistics, missing data and outliers,
and how these were addressed. The results section also includes the testing for covariates
and the testing of assumptions for linear regression models. I devote the last sections of
the chapter to hypothesis testing, with results from the linear regression models assessed
in relation to the null hypotheses of the research questions. A summary concludes the
chapter.
Data Collection
I distributed a total of 1,545 surveys to acute-care nurses in the state of Georgia
through email from March 1, 2016 to April 30, 2016. Of 1,545 surveys sent, 344 (23.8%)
nurses responded to the surveys. I then removed cases if participants (a) did not provide
informed consent (n = 26, 7.6%), (b) did not meet study criteria (n = 46, 13.4%), or (c)
did not answer any of the survey questions (n = 34, 9.9%). This resulted in a sample of N
= 238 nurses who provided informed consent and met study criteria, 69.2% of those who
clicked on the Survey Monkey survey link.
I reviewed the dataset for MNAR data and missing completely at random data.
Eight cases had MNAR data. Of these eight, three (37.5%) did not provide answers to the
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PKS (Bannur et al., 2014) and the PRHDS (Ammouri & Neuberger, 2008) and five did
not answer the PRHDS or the questions regarding taking medication to control blood
pressure. As the data were MNAR, I removed these cases from analyses, lowering the
study sample size to 230, the final sample, 66.9% of those who clicked on the Survey
Monkey survey link. The remaining missing data were missing completely at random,
with a total of 14 missing data points across a total of 12 items (eight PRHDS items and
four PKS items). I used mean imputation to replace missing data.
Descriptive Statistics: Participants
Two hundred and thirty nurses participated in this study. Table 1 presents
demographic and work information from participants. Of these 230 participants, 37
(16.1%) were male and 193 (83.9%) were female. A chi-square (χ²) goodness-of-fit test
determined that this study sample had a significantly higher percentage of male nurses
compared to the population of nurses, χ² (1) = 33.58, p < .001. Almost half of participants
(n = 108, 47.0%) had bachelor’s degrees, and almost a quarter of participants (n = 56,
24.3%) had bachelor’s degrees plus additional training/certification. Of participants, 35
(15.2%) had associate’s degrees, 13 (5.7%) had master’s degrees, and 16 had master’s
degrees plus additional training/certification. Participants indicated a broad range of years
worked as a RN, from less than 1 year to more than 30 years. The majority (n = 132,
57.4%) of participants worked as RNs between 1 and 10 years.
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Table 1
Descriptive Statistics: Demographics of Study Participants (N = 230)
Frequency

Percentage

Gender
Male

37

16.1

193

83.9

Associate’s

37

16.1

Bachelor’s

108

47.0

Bachelor’s plus additional training/certification

56

24.2

Master’s

13

5.7

Master’s plus additional training/certification

16

7.0

Less than 1 year

13

5.7

1–3 years

40

17.4

4–6 years

52

22.6

7–10 years

40

17.4

11–14 years

17

7.4

15–19 years

17

7.4

20–24 years

16

7.0

25–30 years

24

10.4

More than 30 years

11

4.7

Female
Highest level of education

Years worked as a registered nurse

Descriptive Statistics: Covariates
I asked participants if they had any disorders or diseases related to estrogen levels
and if they took medication that is known to affect blood pressure. Descriptive
information on these variables appears in Table 2. The majority of female participants
(n = 168, 81.0%) reported no estrogen-related disorders, diseases, or events, and 48
(20.9%) female participants (100% female) reported one estrogen-related disorder,
disease, or event. Of those 48 participants, seven (14.6%) reported having polycystic
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ovarian syndrome, six (12.5%) reported infertility, and three (6.3%) reported having
endometriosis. In addition, 22 (45.8%) participants reported the event of post menopause
whereas 10 (20.8%) reported the event of having a hysterectomy. Of 100% female
participants, 14 (6.1%) reported two estrogen-related disorders or diseases: specifically,
hysterectomy and post menopause.
I asked participants if they took medication that could affect their blood pressure.
The majority of participants (n = 168, 73.0%) reported not taking such medications and
40 (17.4%) reported taking one medication. Of those 40 participants, 11 (27.5%) reported
taking nonsteroidal anti-inflammatories, seven (17.5%) reported taking estradiol/birthcontrol pills, six (15.0%) reported taking statins, four (10.0%) reported taking synthetic
thyroid-replacement medication, three (7.5%) reported taking diuretics, three (7.5%)
reported taking calcium channel-blocking agents, three (7.5%) reported taking synthetic
estrogen-replacement medication, two (5.0%) reported using an asthma inhaler, and one
(2.5%) reported taking proton-pump inhibitors. Almost three quarters of participants
reported taking no medications that affect blood pressure.
Descriptive Statistics: Study Scales
This study had three primary scales: (a) the PRHDS (Ammouri & Neuberger,
2008), used in this study as an independent and dependent variable, assessed the degree
to which one perceives oneself to be at risk for getting any type of CVD; (b) the PKS
(Bannur et al., 2014), a dependent variable that measured the degree of knowledge about
pharmacogenetic testing for CVD; and (c) the APS (Bannur et al., 2014), a dependent
variable that measured the level of acceptance toward pharmacogenetic testing for CVD.
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Table 2
Descriptive Statistics: Study Participants’ Number of Estrogen-Related Diseases,
Disorders, or Events, and Number of Medications Taken that Affect Blood Pressure
Frequency

Percentage

Number of Estrogen-Related Diseases or Disorders (Female Only, n = 193)
0

131

67.9

1

48

24.9

2

14

7.2

Number of Medications Taken That Affect Blood Pressure (All Participants, N = 230)
0

168

73.0

1

40

17.4

2

15

6.6

3

5

2.2

4

1

0.4

5

1

0.4

Scale Development and Computations
The 20-item PRHDS measures the degree to which one perceives oneself at risk
for any type of CVD. The PRHDS, on which 12 of the 20 items are reverse-scored,
comprises three subscales. The 7-item Unknown Risk subscale comprises items that
assess external locus of control aspects of risk for CVD; an example is “No matter what I
do, if I am going to get heart disease, I will get it.”
The computation of the PRHDS was initiated by recoding the 12 reverse-scored
items to correspond to the scoring of the other 8 items. I then examined the scale interitem reliability by computing the Cronbach’s alpha for the total PRHDS scale. The
Cronbach’s alpha was an unacceptable .60 for the overall PRHDS. A review of
Cronbach’s alpha values if certain items were deleted from the scale showed that the
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seven Unknown Risk items were the cause of the low Cronbach’s alpha. When I removed
these seven items, the Cronbach’s alpha was a very acceptable .77. This study thus used a
13-item PRHDS, comprised of the two subscales of Dread Risk and Risk.
I scored the 5-item PKS, used to measure knowledge of pharmacogenetic testing
for CVD, as though it was a test or examination, using a scale from 0% to 100%. Due to
the true/false scoring of the PKS, I could not compute a Cronbach’s alpha. The APS
measured acceptance of pharmacogenetic testing for CVD. Outlier boxplots and unusual
case-function testing revealed that the APS had two outliers, both of which were
extremely low scores of 11. I winsorized these two scores, replacing them with the next
lowest score, which was 15. Outlier boxplots and unusual case-function testing revealed
no univariate outliers for the PRHDS and PKS. The computation of the Mahalanobis
distances uncovered no multivariate outliers.
The descriptive statistics for these three scales appear in Table 3. Information
included in Table 3 includes the zskewness value of the scale. This is an indicator of
normality: zskewness values less than +/-1.96 indicate relative normality (Kim, 2013). I
report Cronbach’s alphas (αs) as indicators of inter-item reliability for the APS and
PRHDS scales. A Cronbach’s α greater than or equal .70 indicates acceptable inter-item
reliability (Garson, 2012).
The mean score on the PRHDS was 26.30 (SD = 4.97), with PRHDS scores
ranging from 13.00 to 40.00 points. The mean was relatively low, and the range of scores
did not extend to the highest possible score of 52. These descriptive statistics suggested
participants perceived they had a relatively low risk for developing CVD. PRHDS
nonetheless had a normal distribution of scale scores, as indicated by a zskewness value
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of -1.65. The Cronbach’s α of the PRHDS was good, with a Cronbach’s α of .77. The
mean score on the PKS was 68%, equivalent to a D+, and scores on the PKS ranged from
0% to 100%. The zskewness value of -1.55 indicated that the PKS had relative normality.
The mean score of the APS was 31.77 (SD = 5.13), and scores on the APS ranged from
15.00 to 45.00 points. The APS had an acceptable zskewness value of -1.77, indicating
relative normality and the inter-item reliability of the APS was sound, with a Cronbach’s
α of .75.
Table 3
Descriptive Statistics: Attitude Toward Pharmacogenomics Scale, Pharmacogenomics
Knowledge Scale, and Perceived Risk for Heart Disease Scale (N = 230)
M

SD

Min

Max

zskewness

Alpha

Perceived Risk for Heart Disease
Scale (PRHDS)

26.30

4.97

13.00

40.00

-1.65

.77

Pharmacogenomics Knowledge
Scale for CVD (PKS)

0.68

0.19

0.00

1.00

-1.55

31.77

5.13

15.00

45.00

-1.77

Attitudes toward
Pharmacogenomics for CVD
Scale (APS)

N/A
.75

Note. M = mean, SD = standard deviation, Min = minimum score, Max = maximum score. zskewness =
skewness/standard error of skewness; and α = Cronbach’s alpha; The possible range of scores on the
PRHDS is 13.00–52.00 points. The possible range of scores on the PKS is 0%–100%. The possible range
of scores on the APS is 9.00–45.00 points.

Testing of Covariates
I included the questions about estrogen-related diseases, disorders, and events,
and the medications taken that could affect blood pressure in the study survey as potential
covariates; that is, I thought they would significantly relate to the dependent variables of
(a) perception of risk for heart disease, as measured by the PRHDS; (b) pharmacogenetic
testing knowledge, as measured by the PKS, and (c) acceptance of pharmacogenetic
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testing, as measured by the APS. I summed the total scores of the estrogen-related
diseases, disorders, and event items and the medication that could affect blood pressure
items, dichotomized so that 1 = presence of disease, disorder, or event or take at least one
medication and 0 = absence of disease, disorder, or event and do not take any medication.
I then conducted Spearman’s rho, with results presented in Table 4.
As seen on Table 4, although the variable of having estrogen-related diseases,
disorders, or events did not significantly associate with perceptions of risk for CVD, the
variable of take medications that could affect blood pressure did significantly associate
with this dependent variable, rs(230) = .14, p = .038. I included take medication that
could affect blood-pressure in the analyses to test Research Questions 1 through 3.
Neither presence/absence of estrogen-related diseases, disorders, or events, or currently
taking medication that could affect blood pressure significantly aligned with acceptance
of pharmacogenetic testing or with knowledge of pharmacogenetic testing. Thus, I
included neither item as a covariate in the analyses to test Research Questions 4 through
7.
I conducted one Pearson bivariate correlation between pharmacogenetic testing
knowledge and acceptance of pharmacogenetic testing. The result from the Pearson
bivariate correlation showed significance, r (230) = .14, p = .043, indicating that, as
knowledge of pharmacogenetic testing increased, so did acceptance of such testing. I
entered the variable of pharmacogenetic-testing knowledge as a covariate in the analyses
to test Research Question 8.
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Table 4
Spearman’s Rho Correlations: Estrogen-Related Diseases, Disorders, or Events, and
Currently Take Medications That Could Affect Blood Pressure and Attitude Toward
Pharmacogenomics Scale and Pharmacogenomics Knowledge Scale (N = 230)
Perception of Risk for
Heart Disease Scale
(PRHDS)

Attitudes toward
Pharmacogenomics
Scale for CVD (APS)

Pharmacogenomics
Knowledge for CVD
Scale (PKS)

Have estrogen-related
disease, disorder, or event
(Y/N)

.08

-.03

-.12

Take medications that could
affect blood pressure (Y/N)

.14*

-.03

-.07

Note. CVD = cardiovascular disease; *p < .05

Testing of Assumptions for Linear Regression Models
HMLR, conducted to address Research Questions 1 through 3, MLR, conducted
to address Research Questions 4 through 7, and HLR, conducted to address the eighth
research question all had the same assumptions: (a) normality of continuously-coded
independent and dependent variables; (b) lack of multicollinearity between independent
variables; (c) independence of errors in linear regression/HLR results; and
(d) homoscedasticity of errors in linear regression/HLR results (Garson, 2012). Normality
was already addressed by computing zskewness values, and the three study variables had
zskewness under 1.96, signifying the normality assumption was met. The three remaining
assumptions were tested, with results presented in the following sections.
Assumption of Lack of Multicollinearity
I assessed multicollinearity, or high correspondence between independent
variables so they essentially are measuring the same construct (Garson, 2012; Kleinbaum
et al., 2013), by computing Spearman’s rho correlations and VIFs among the independent
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variables of highest level of education, years of working as a RN, and gender. A
Spearman’s rho correlation of rs >= .90, p < .001 and a VIF > 10.00 indicate
multicollinearity (Garson, 2012; Kleinbaum et al., 2013).
I did not expect these demographic and work variables to display multicollinearity,
and results from the Spearman’s rho correlation analyses and the computing of VIFs
supported this expectation. Gender significantly correlated with years worked as a RN,
rs(230) = .20, p = .003: being female significantly aligns with increased number of years
worked as an RN. The correlation coefficient of rs = .20 was well below the critical
coefficient value of rs = .90. All VIFs were considerably below the critical value of 10.00.
Multicollinearity was not evident in these findings. The assumption of lack of
multicollinearity was met (see Table 5).
Table 5
Testing for Multicollinearity: Spearman’s Rho Correlation Coefficients and Variance
Inflation Factors (N = 230)
Highest level of
education

Years as a registered
nurse

Gender

Highest level of education

—

1.00

1.04

Years as registered nurse

.06

—

1.00

Gender

-.01

.20*

—

Note. *p < .05. Spearman’s rho correlations are below the diagonal and variance inflation factors are above
the diagonal.

Assumption of Independence of Errors
I tested the assumption of independence of errors, or the lack of autocorrelation
among errors, by calculating Durbin-Watson values for each HMLR/MLR/HLR model.
Durbin-Watson values between 1.00 and 3.00 indicated this assumption was met (Garson,
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2012; Kleinbaum et al., 2013). The Durbin-Watson values for each model of the three
regression analyses conducted appear in Table 6. As can be seen in Table 6, all DurbinWatson values fell between 1.00 and 3.00, signifying that the assumption of
independence of errors was met for all models in the regression analyses.
Table 6
Testing for Independence of Errors: Durbin–Watson Values for Each Regression
Analysis for Hypothesis Testing (N = 230)

Durbin–Watson Value

HMLR for RQs 1–3

MLR for RQs 4–7

HLR for RQ 8

1.86

2.04

1.94

Note. HMLR = hierarchical multiple linear regression; RQ = research question; MLR = multiple linear
regression; HLR = hierarchical linear regression.

Assumption of Homoscedasticity of Errors
I tested the assumption of homoscedasticity of errors, or the constancy of errors in
linear regression analyses, by plotting residuals using scatterplots. If the data points
displays an equivalent distribution above and below the horizontal line at zero, this
assumption has been met (Garson, 2012; Kleinbaum et al., 2013). I computed three
scatterplots for each of the three linear regression analyses. As shown in Figures 3, 4, and
5, the distribution of error data points was equivalent above and below the horizontal zero
for each scatterplot. The assumption of homoscedasticity of errors was met for each
linear regression model.
Hypothesis Testing
This study posed seven research questions. As stated in Chapter 3, one MLR
addressed Research Questions 1 through 3 as were Research Questions 4 through 6. An
HLR addressed the seventh and last research question. This section of the chapter is
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structured to present the results from the MLRs, followed by a presentation of results for
each research question, with reference to whether the results supported the rejection or
acceptance of the null hypothesis.

Figure 2. Scatterplot of residuals: Medication that could affect blood pressure, highest
level of education, years worked as a registered nurse, and gender predicting perceived
risk for CVD.

Figure 3. Scatterplot of residuals: Highest level of education, years worked as registered
nurse, and gender predicting knowledge of pharmacogenetic testing.
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Figure 4. Scatterplot of residuals: Knowledge of pharmacogenetic testing and perceived
risk for CVD predicting acceptance of pharmacogenetic testing.
Hierarchical Multiple Linear Regression 1: Research Questions 1–3
The first through third research questions examined if highest level of education,
years worked as a RN and gender were significant predictors of perceived risk for CVD. I
entered take medication that could affect blood pressure as a covariate in the first model
of the HMLR, as it significantly correlated with perception of risk for CVD. I entered all
three independent variables as predictors of perception of risk for CVD on the second
model of the HMLR.
Results from the HMLR appear in Table 7. The first model of the HMLR, with
take medication that could affect blood pressure entered as a predictor of perceived risk
for CVD, was significant, F(1, 228) = 3.80, p = .046, R2 =.016. Based on the coding of
the predictor variable, this finding indicated that taking medication that could affect
blood pressure significantly aligned with higher perceived risk for CVD, β(230) = .140,
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p = .046. The second model, in which the independent variables of highest level of
education, years worked as a RN, and gender predicted perceived risk for CVD, was
significant, Fchange (3, 225) = 2.85, p = .038, R2change = .036. However, only gender
emerged as a significant predictor of perceived risk for CVD, β (230) = -.163, p = .015.
Based on the coding of the gender variable, this significant result indicated that being
male significantly aligned with increased perceived risk for CVD.1 The covariate of take
medication that could affect blood pressure was no longer a significant predictor of
perception of risk for CVD, β (230) =.122, p = .066 in the second model of the HMLR.
Table 7
Hierarchical Multiple Linear Regression (HMLR): Take Medication That Could Affect
Blood Pressure (Covariate), Highest Level of Education, Years Worked as a Registered
Nurse, and Gender Predicting Perceived Risk for Cardiovascular Disease (N = 230)
Model 1
B
Medication

1.42

SE B
.749

Model 2
β
.140*

Level of education
Years worked as an RN
Gender

p

SE B

β

1.35

.731

.122

-.445

.310

-.094

.178

.147

.082

.895

-.163*

-2.20

R2
F for R

B

.016
2

3.80
.046

.036
2.85
.038

Note. RN = registered nurse; *p < =.05

Research Question 1. The first research question was, “Is there a significant
association between nurses’ years of education and perceived risk for CVD?” Results
1 An

independent samples t-test confirmed this finding. Male nurses had a significantly higher mean scores
on the PRHDS (n = 37, M = 27.86, SD = 4.63) than did female nurses (n = 193, M = 26.00, SD = 4.99),
t(228) = 2.11, p = .036
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from the HMLR showed no significant associations between nurses’ years of education
and perceived risk for CVD, β (230) = -.094, p = .153. Based on the nonsignificant
findings, I retained the null hypothesis, “There is no association between nurses’ years of
education and perceived risk for CVD.”
Research Question 2. The second research question was, “Is there a significant
association between nurses’ years of practice and perceived risk for CVD?” Results from
the MLR showed that nurses’ years of practice was not significantly associated with
perceived risk for CVD, β (230) = .082, p = .226. Due to the lack of significant findings, I
retained the null hypothesis, “There is no association between nurses’ years of practice
and perceived risk for CVD.”
Research Question 3. The third research question was, “Is there a significant
association between nurses’ gender and perceived risk for CVD?” Results from the MLR
showed that gender did significantly align with perceived risk for CVD, β (230) = -.163,
p = .015. Based on the coding of the gender variable, this significant result indicated that
being male significantly aligned with increased perceived risk for CVD. The significant
findings led to the rejection of the null hypothesis, “There is no association between
nurses’ gender and perceived risk for CVD.”
Multiple Linear Regression 2: Research Questions 4–6
The fourth through sixth research questions examined if highest level of education,
years worked as a RN and gender were significant predictors of knowledge of
pharmacogenetic testing for CVD. As no demographic variables significantly correlated
with the dependent variable of knowledge of pharmacogenetic testing for CVD, only one
model was required for the regression analysis. The collective entry of the three
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independent variables in one model as predictors of knowledge of pharmacogenetic
testing for CVD required the use of an MLR.
Results from the MLR appear in Table 8. The overall regression model was not
significant, F (3, 226) = 1.94, p = .095, R2 =.024. When examining individual predictors,
however, one variable, highest level of education, did significantly align with knowledge
of pharmacogenetic testing for CVD, β (230) = .164, p = .042. As education level
increased, so did knowledge of pharmacogenetic testing for CVD.
Table 8
Multiple Linear Regression: Highest Level of Education, Years Worked as a Registered
Nurse, and Gender Predicting Knowledge of Pharmacogenetic Testing for
Cardiovascular Disease (N = 230)
Model 1
B
Level of education
Years worked as an RN
Gender
R2

Β

.043

.022

.164*

-.009

.006

-.103

.024

.035

.046

.024

F for R2
p

SE B

1.94
.095

Note. RN = registered nurse; *p < =.05

Research Question 4. The fourth research question was, “Is there a significant
association between nurses’ years of education and knowledge of pharmacogenetic
testing for CVD?” Results from the MLR showed significant associations between nurses’
years of education and knowledge of pharmacogenetic testing for CVD, β (230) = .164,
p = .042. As years of education increased, so did knowledge of pharmacogenetic testing
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for CVD. The significant findings led to the rejection of the null hypothesis, “There is no
association between nurses’ years of education and knowledge of pharmacogenetic
testing for CVD.”
Research Question 5. The fifth research question was, “Is there a significant
association between nurses’ years of practice and knowledge of pharmacogenetic testing
for CVD?” Results from the MLR showed that nurses’ years of practice did not
significantly align with knowledge of pharmacogenetic testing for CVD, β (230) = -.103,
p = .126. Due to the lack of significant findings, I retained the null hypothesis, “There is
no association between nurses’ years of practice and knowledge of pharmacogenetic
testing for CVD.”
Research Question 6. The sixth research question was, “Is there a significant
association between nurses’ gender and knowledge of pharmacogenetic testing for CVD?”
Results from the MLR showed that gender did not significantly align with perceived risk
for CVD, β (230) = .046, p = .495. As I found no significant results, the null hypothesis, I
retained “There is no association between nurses’ gender and knowledge of
pharmacogenetic testing for CVD.”
Hierarchical Linear Regression: Research Question 7
The seventh and last research question examined whether a significant association
existed between nurses’ perceived risk for CVD and their acceptance of pharmacogenetic
testing for CVD. As knowledge of pharmacogenetic testing for CVD significantly aligned
with acceptance of pharmacogenetic testing for CVD, I entered it as a covariate in the
first model of the HLR. I entered the single predictor of perceived risk for CVD on the
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second model of the HLR as a predictor of acceptance of pharmacogenetic testing for
CVD.
Results from the HLR appear in Table 9. The first regression model, with
knowledge of pharmacogenetic testing for CVD predicting acceptance of
pharmacogenetic testing for CVD, was significant, F(1, 228) = 3.86, p = .048, R2 = .017.
As knowledge of pharmacogenetic testing for CVD increased, so did acceptance of
pharmacogenetic testing, β (230) = .134, p = .048. The second model of the HLR, with
perceived risk of CVD entered as a predictor of acceptance of pharmacogenetic testing,
was not significant, F(1, 227) = 2.78, p = .097, R2 =.012. Knowledge of pharmacogenetic
testing nonetheless remained a significant predictor of acceptance of pharmacogenetic
testing, β (230) = .129, p = .049, in the second regression model. Based on the lack of
significance between perceived risk for CVD and acceptance of pharmacogenetic testing,
I retained the null hypothesis for Research Question 7.
Summary
I conducted this quantitative study, which used a correlational research design,
with 230 RNs working in acute-care settings in hospitals throughout the State of Georgia.
The sample of 230 nurse participants was 66.9% of the original group of 344 nurses who
accessed the Survey Monkey link. A substantial number of nurses (n = 26) did not
provide consent and an additional 34 nurses did not complete the study survey even after
having provided consent and meeting study criteria. The sample of 230 was nonetheless
robust to achieve power at .80. An equal number (n = 168) of nurses reported never
having had estrogen-related diseases, disorders, or events and not currently taking any
medication that could affect their blood pressure.
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Table 9
Hierarchical Linear Regression: Knowledge of Pharmacogenetic Testing for
Cardiovascular Disease (Covariate) and Perceived Risk for Cardiovascular Disease
Predicting Acceptance of Pharmacogenetic Testing for Cardiovascular Disease (N =
230)
Model 1
B

SE B

3.47
1.75
Knowledge of
pharmacogenetic
testing for CVD
Perceived risk for
CVD
R2
.017
2
F for R
3.86
p
.048
Note. CVD = cardiovascular disease; *p < =.05.

Model 2
Β
.134*

B

SE B

3.45

1.85

-.113

.068

Β
.129*

-.109

.012
2.78
.097

The descriptive statistics on the study variables provided additional insights into
the sample of nurses in this study. The mean score on the PRHDS scale was relatively
low, indicating that, as a group, these nurses did not perceive themselves to be at risk for
CVD. The score on the APS indicated that participants had neither high nor low levels of
acceptance of pharmacogenetic testing for CVD. The participants had low levels of
knowledge of pharmacogenetic testing for CVD, based on the mean PKS test score of
68%.
I conducted three types of linear regression models (HMLR, MLR, and HLR) for
hypothesis testing, and a few findings were found to be significant. Male gender
significantly aligned with increased perceived risk for CVD; that is, male nurses reported
higher levels of perceived risk for CVD than did female nurses. Highest level of
education emerged as significantly associated with increased knowledge of
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pharmacogenetic testing: as education level increased, so did knowledge of
pharmacogenetic testing. Other findings that emerged as significant included significant
associations between taking medications that could affect blood pressure with increased
perceived risk for CVD and knowledge and acceptance of pharmacogenetic testing for
CVD. I discuss these findings in greater detail, especially in relation to previous research,
in Chapter 5.
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Chapter 5: Introduction
The U.S. healthcare system has become a patient-centered medical community
that is quickly adopting pharmacogenetic testing practices for CVD (ANA, 2015; Heller
et al., 2014). The knowledge base of nurses has grown beyond basic CVD concepts, and
nurses increasingly need to have knowledge of pharmacogenetic testing for CVD to best
advocate for such testing and translate the meaning of such testing to their patients (ANA,
2015). However, empirical evidence suggests that nurses have limited understanding of
pharmacogenetic testing (Bannur et al., 2014; Roederer et al., 2012). This lack of
knowledge coupled with nurses’ perceptions of being at low risk for CVD, despite having
numerous CVD risk factors, may lead to resistance in advocating for the use of
pharmacogenetic testing for CVD, which can ultimately impair patient health.
This quantitative study, which had a response rate of 14.9%, was conducted with
230 predominantly (83.9%) female RNs working in acute-care medical settings in the
state of Georgia. The study was guided by Rosenstock’s (1978) HBM. In the first set of
research questions, I examined, through HMLR, if the modifying factors of nurse gender,
highest level of education, and years of experience significantly predicted nurses’
perceived risk for CVD, controlling for taking medication that could affect blood
pressure. Only one independent variable, gender, was significant: men more than women
perceived themselves to be at increased risk for CVD. The covariate of taking medication
that could affect blood pressure also significantly predicted perceived risk for CVD. The
second set of research questions examined, through MLR, if these same modifying
factors significantly predicted nurses’ knowledge of pharmacogenetic testing for CVD.
Highest level of education was the only significant predictor of knowledge of
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pharmacogenetic testing for CVD; as education level increased, so did knowledge. The
last research question, which I addressed through the use of an HLR, inquired as to
whether perceived risk for CVD significantly aligned with acceptance of
pharmacogenetic testing for CVD, controlling for knowledge of pharmacogenetic testing
for CVD. Perceived risk for CVD was not a significant predictor of acceptance of
pharmacogenetic testing for CVD (the covariate of knowledge of pharmacogenetic
testing for CVD was significant).
Interpretation of the Findings
I had empirical and theoretical goals that I attempted to achieve with this
quantitative study. My primary empirical goal was to enhance understanding of nurses’
perceived risk for CVD and if certain demographic modifying factors significantly
contributed to these perceptions. Researchers documented that nurses have numerous
health, mental health, and health-related behaviors and demographic risk factors for CVD
(ANA, 2015; Baer et al., 2011; Fair et al., 2009; Louie & Wedell, 2014; Khan et al.,
2012) and yet, as a group, nurses do not perceive themselves to be at risk for developing
CVD (Jones et al., 2006). An additional goal was to address gaps in the nursing literature
concerning nurses’ knowledge and attitudes toward pharmacogenetic testing.
Rosenstock’s (1974) HBM provided a theoretical framework from which to examine
these constructs and relationships. This section of the chapter is devoted to an
examination of the study findings. I discuss the results in relation to prior empirical work
conducted on pertinent study constructs as well as the applicability of Rosenstock’s
(1974) HBM.
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Interpretation of Findings: Comparisons to Prior Research Findings
The first goal of this study was to determine if the demographic modifying factors
of gender, highest level of education, and years worked as an RN significantly predicted
increased levels of perceived risk for CVD. Evidence from this study showed that male
gender did significantly align with increased perceived risk for CVD among nurses (as
was the covariate of taking medication for blood pressure). Although no studies have
examined these associations with samples of healthcare providers, an extensive body of
research has examined actual and perceived risk for CVD among diverse patient groups
(Imes & Lewis, 2014). In their review of the literature on the contribution of
demographic and health factors on patients’ perceived risk for CVD, Imes and Lewis
(2014) reported equivocal findings across studies with regard to patient gender. The
researchers posited that the inconsistencies in gender differences and perceived risk for
CVD were a result of the diversity of study-participant samples, noting that gender results
were likely obscured by other modifiable (e.g., education level, history of tobacco use,
obesity/ overweight, cholesterolemia, diagnosis of Type 2 diabetes) and unmodifiable
(e.g., age, ethnicity, genetic predisposition) risk factors for CVD.
This study further examined nurses’ knowledge of pharmacogenetic testing and
the influence of gender, education level, and years of experience on such knowledge.
Results from this study showed that education level but not gender or years worked as a
RN was significant predictors of knowledge of pharmacogenetic testing for CVD. Social
science studies that examined healthcare practitioners’ perceptions of pharmacogenetic
testing have tended to focus on physicians and pharmacists (Yáu, Husain, & Haque,
2015), even while acknowledging that the successful implementation of pharmacogenetic
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testing is the nurse’s attitudes toward it (Chadwell, 2013). To this end, researchers know
little of the personal characteristics of nurses that significantly align with knowledge of
pharmacogenetic testing for CVD. Researchers showed that few differences exist in the
profession, as a substantial majority, 66% to 84% of physicians, pharmacists, and nurses,
reported having low levels of pharmacogenetic testing knowledge (Dodson, 2011;
Dodson & Van Riper, 2011). Roederer et al. (2012) examined pharmacogenetic testing
knowledge and attitudes among pharmacists. Results from the Roederer et al. study
showed that, similar to the results in this study, pharmacists with higher levels of
education (i.e., doctorates) had higher levels of pharmacogenetic testing knowledge than
did pharmacists with lower levels of education.
An interesting finding in the Roederer et al. (2012) study was that pharmacists
who matriculated within the prior 5 years and thus had fewer years of experience, had
higher level of pharmacogenetic testing knowledge than did pharmacists who
matriculated over 5 years prior and thus had more years of experience. Moreover,
pharmacists who had matriculated more than 30 years prior had the lowest
pharmacogenetic-testing-knowledge scores (Roederer et al., 2012). Although the results
were not significant in this study with regard to years of experience, they did show a
negative relationship between nurses’ years of experience and pharmacogenetic-testing
knowledge, suggesting that a similar finding might arise among nurses. The Roederer et
al. findings suggested that exposure to pharmacogenetic testing is more a function of the
contemporary healthcare educational system and less a function of on-the-job exposure to
pharmacogenetic testing.
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The final research question of this study examined whether nurses’ perceived risk
for CVD led to significant increases in acceptance of pharmacogenetic testing for CVD.
Results were not significant. Empirical work on acceptance of pharmacogenetic testing
has predominantly focused on the acceptance of pharmacogenetic testing among patients.
The literature on patient factors has documented consistent linkages between the specific
patient demographic factors of young-adult status (i.e., ages 18–34 years), Caucasian
ethnicity, and higher levels of education, and increased levels of acceptance of
pharmacogenetic testing for CVD (Chan & Perry, 2012; Haga, O’Daniel, Tindall, Lipkus
et al., 2012; Haga, O’Daniel, Tindall, Mills et al., 2012). In contrast, highest level of
education was not a significant predictor of acceptance of pharmacogenetic testing for
CVD among nurses in this study. I could locate no studies that examined the relationship
between perceived risk for CVD and acceptance of pharmacogenetic testing for CVD in
patients or healthcare providers.
Results from this study also provided descriptive information on current topics
highly relevant to the nursing field. The mean score on the Bannur et al. (2014) PKS in
this study was 68%. The percentage of participants who failed the PKS, 14%, was higher
than the percentage of study participants who received a score of 100%: 9.6%. These
findings suggested a poor understanding of pharmacogenetic testing among nurses in this
study. Kadafour et al. (2009) and Van Riper et al. (2011) found similar results,
documenting mean pharmacogenetic-testing-knowledge test scores of 40% and 60.3%,
respectively, among nurses.
Another finding was that nurses perceived themselves to be at low risk for CVD.
Substantial evidence exists from a robust body of empirical literature that nurses have
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numerous modifiable and unmodifiable risk factors for CVD (ANA, 2015; Baer et al.,
2011; Chan & Perry, 2012; DPE, 2012; Fair et al., 2009; Khan et al., 2012; Lang et al.,
2012; Li et al., 2006; Louie & Wedell, 2014; McElligott et al., 2009; Nahm et al., 2012;
Puett et al., 2009; Slater et al., 2005). However, the strong empirical focus on actual CVD
risk factors in nurses has not, surprisingly, prompted empirical work on nurses’ perceived
risk for CVD. The only work to date that has focused on nurses’ perceptions of their risk
for developing CVD has been the qualitative study by Jones et al. (2006), who
documented perceived low risk of CVD in a sample of African American nurses, despite
this group having numerous risk factors for CVD. The results from the Jones et al. study
align with results from this study.
Interpretation of Findings: Comparisons to Health-Belief Model Framework
This study tested various pathways delineated among health-factor variables
proposed by Rosenstock (1974) in the HBM. The first three research questions tested
theoretical relationships between the modifying factors of gender, highest level of
education, and years of practice and the perception of susceptibility factor of perceived
risk for CVD. The only modifying factor found to be significant was gender, with male
nurses perceiving themselves to be at greater risk for CVD than female nurses. The fourth
through sixth research questions tested if the modifying factors of gender, highest level of
education, and years of practice significantly predicted the perceived benefits versus
barriers factor of knowledge of pharmacogenetic testing for CVD. Highest level of
education emerged as the only significant predictor of increased knowledge for
pharmacogenetic testing for CVD. The seventh and last research question examined the
relationship between the perception of susceptibility factor of perceived risk for CVD and
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the likelihood of action behavior of acceptance of pharmacogenetic testing for CVD.
Results indicated that nurses’ perceptions of their CVD risk did not significantly affect
their acceptance of pharmacogenetic testing for CVD.
The overall study findings did not provide support for the HBM in the context of
nurses’ perceptions of their risk for CVD, their knowledge of pharmacogenetic testing for
CVD, or their acceptance of pharmacogenetic testing for CVD. One assumption of the
HBM is that individuals have the capacity to change their health-related behaviors for
health promotion and disease prevention (Rosenstock, 1974; Rosenstock et al., 1988,
1994). In this study, this idea was taken a step further: I posited that nurses’ perceptions
of their own risk for CVD would lead to an increased acceptance of pharmacogenetic
testing for CVD, which would likely influence their own health behaviors as well as the
health behaviors of their patients. Although not a focus of this study, I found that nurses’
knowledge of pharmacogenetic testing, considered to be a theoretical perception of
benefits versus barriers of health behavior factor, did influence their likelihood of action
to accept pharmacogenetic testing for CVD. Results from this study suggest that the
personal health of nurses is not nearly as important as their knowledge of
pharmacogenetic testing for CVD in influencing their acceptance of such practices.
Limitations of the Study
Objectivity is of the utmost importance in empirical research, and a certain degree
of objectivity is not only necessary but required to reach sound study conclusions
(Stangor, 2014). However, research conducted with human subjects, especially research
using nonexperimental methods, often has methodological, design, and data limitations
that can reduce study objectivity and quality (Stangor, 2014). Although the link to the
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study survey was sent to 1,545 nurses, only 344 nurses responded to the survey.
Moreover, I removed 114 of the 344 cases from the data set due to some participants not
providing informed consent, others not meeting study criteria, and still others not
completing the survey. Although the sample of 230 nurses was large enough to achieve
the desired power, it was a concern that the response rate was only 14.9%. A large
nonresponse bias may increase the likelihood of self-selection bias in that participants
who responded to the survey may have differed in some ways from those who did not.
For example, participants who completed the study survey may have had fewer risk
factors for CVD and thus perceived themselves to be at less risk for CVD, or they may
have had more knowledge of pharmacogenetic testing for CVD. Both nonresponse and
self-selection bias make it difficult to generalize study findings to the population of RNs
working in acute-care settings in Georgia.
The large nonresponse rate may have resulted from another limitation of using a
convenience sample of nurses. Convenience sampling increased the likelihood that
participants in this study were not a representative sample of the population of RNs
working in acute-care settings in Atlanta, Georgia, which limited the generalizability of
study findings and the external validity of this study (Stangor, 2014). Another limitation
of this study was the use of a quantitative cross-sectional research design, which
precluded the ability to infer cause and effect (as suggested by Stangor, 2014).
Although researcher objectivity is a desired goal, researchers are human and are
not necessarily neutral or value free (Stangor, 2014). In parallel, a possibility exists that
participants differ in their understanding and interpretation of survey questions, which
may have influenced study data (aligned with Stangor, 2014). The low pharmacogenetic-
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testing-knowledge score and its alignment with results from prior studies suggests that
study participants were being truthful about their knowledge. They may have been less
truthful about their perceptions of CVD risk. The instrument measuring nurses’
perceptions of risk for CVD displayed poor inter-item reliability, necessitating that I use a
shortened version of the instrument.
Recommendations
I hope this study acts as a catalyst to promote additional empirical work as it
pertains to nurses’ CVD health and their knowledge and acceptance of pharmacogenetic
testing for CVD as well as the applicability of Rosenstock’s (1974) HBM to these topics
and relationships. This study adds to the small body of literature (e.g., Jones, 2006) that
has documented that, despite having numerous risk factors for CVD, nurses do not
perceive themselves to be at risk for CVD. Additional empirical work is needed to further
validate these results, as are studies that compare nurses’ actual versus perceived risk for
CVD. Results from this study combined with those found in the Roederer et al. (2012)
study suggest that recent matriculation may play more of a role than does length of
experience in influencing nurses’ knowledge of pharmacogenetic testing for CVD.
Studies are needed that examine the linkages between nursing school curricula, required
nursing courses, and exposure to and training in pharmacogenetic-testing procedures and
nurses’ knowledge and acceptance of pharmacogenetic testing for CVD. In parallel,
studies that assess improvements in nurses’ knowledge and acceptance of
pharmacogenetic testing for CVD as a result of their participation in professionaldevelopment opportunities on pharmacogenetic testing for CVD are needed.
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This study operationally defined HBM theoretical constructs and examined
theoretical pathways in very specific ways. Results from this study did not lend strong
support for the HBM. It may be that this study examined two research topics—perceived
risk for CVD among nurses versus nurses’ knowledge and acceptance of
pharmacogenetic testing for CVD—that shared little theoretical overlap. However, both
topics have been recognized as having empirical relevance. A need persists for studies
that use the HBM theoretical pathway to provide a more cohesive and comprehensive
picture of factors that influence and are influenced by nurses’ health factors as they
pertain to CVD compared to those that concern nurses’ knowledge and acceptance of
pharmacogenetic testing for CVD.
Implications for Social Change
The positive social change that can result from this study’s findings include a
direct impact on nursing knowledge and training through the development of targeted
educational materials for acute-care nurses (and ultimately, patients) about CVD risk
factors and pharmacogenetic testing, on patient health outcomes, and on the
empowerment of acute-care nurses to act as patient advocates. Developing a better
understanding of demographic and CVD risk factors among acute-care nurses will allow
for specific intervention and targeted educational programs in nursing schools and
training programs in healthcare organizations. Moreover, results from this study may
facilitate future research on how acute-care nurses’ perceptions of CVD risk factors and
pharmacogenetic testing influence their patient-care practices and patient advocacy,
including increasing patient awareness and knowledge of CVD risk factors and the
benefits of pharmacogenetic testing.
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Conclusion
This quantitative study investigated if acute-care nurses’ gender, highest level of
education, and years of nursing practice significantly influenced their perceived risk for
CVD and their knowledge of pharmacogenetic testing for CVD, and whether significant
associations exist between nurses’ risk for CVD and acceptance of pharmacogenetic
testing for CVD. The data analysis revealed some significant association between the
independent and dependent variables in the seven research questions. Male gender
significantly aligned with increased perceived risk for CVD more than female nurses.
Highest level of education significantly aligned with increased knowledge of
pharmacogenetic testing: as education level increased, so did knowledge of
pharmacogenetic testing. Significant associations emerged between taking medications
that could affect blood pressure with increased perceived risk for CVD and knowledge.
The field of pharmacogenetic testing has existed for over 60 years; however, the
empirical body of CVD pharmacogenetic testing literature is only a decade old (Tonk,
Gurwitz, Maitland-van der Zee, & Janssens, 2016). Pharmacogenetic-testing empirical
literature is still in its infancy. Studies in clinical biochemistry, behavioral genetics,
pharmaceutical chemistry, and molecular biology are continuing to greatly eclipse the
body of social science literature, especially studies on healthcare practitioners’
knowledge, use, and attitudes toward pharmacogenetic testing. A dearth of literature
persists on the CVD health of nurses as well as their knowledge and acceptance of
pharmacogenetic testing for CVD. The crucial role that nurses’ play in their patients’
achievement of their heart health necessitates that further research be conducted on these
topics.
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